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ABSTRACT 
Tumors are complex diseases that are caused by a combination of environmental, lifestyle and 
genetic factors and they can originate from almost any cell type of the human body. Majority of 
tumors occur in isolated patients, but a fraction aggregate in families. In rare cases, familial 
aggregation of tumors is caused by inheritance of a mutated gene, which results in a high risk to 
develop specific tumors. About 1-5% of common cancers are estimated to be caused by 
inheritance of such genes. Although these patients constitute only a small fraction of all cancer 
patients, identification of these genes has improved significantly our understanding of the 
molecular basis of cancer as well as patient care and surveillance.  
Over one hundred high risk tumor susceptibility genes have been identified during past few 
decades, but some remain yet to be characterized. These include those that do not cause other 
clinically recognizable syndromic features, and present with varying or incomplete penetrance. 
One aim of this study was to assess the familial aggregation of cancers in Finland and to identify 
novel tumor susceptibility conditions and families by systematically analyzing the population 
based patient data at the Finnish Cancer Registry (FCR). Another purpose of this study was to 
identify and characterize novel tumor susceptibility genes from families obtained from the FCR 
search as well as from medical genetics clinics. 
In the first study, to assess the familial aggregation of tumors and to identify novel tumor 
susceptibility families, we conducted a systematic computerized clustering of the entire FCR 
patient database. Altogether 878 593 patients, diagnosed in 1952-2011, were clustered based on 
family name at birth, municipality of birth, and tumor type. Additional clustering based on family 
name at birth and tumor type was also conducted. For all clusters, observed and expected ratio, 
with 95% confidence intervals, were calculated. This yielded 25 910 family name at birth, 
municipality of birth, and tumor type based clusters, and 12 695 family name at birth and tumor 
type based clusters, representing 183 different tumor types.  
We assessed the familial occurrence of the different tumors by a cluster score that proportions the 
patients in the most significant clusters to the frequency of the given tumor type in Finland. AS 
expected, ranking of the tumor types based on the cluster score showed that most frequently 
clustered tumor types included those of well-known genetic background, such as thyroid 
medullary carcinoma, Wilms’ tumor and retinoblastoma, but also those of unknown genetic 
etiology such as Kaposi Sarcoma (KS). We performed genealogy analysis on the clustered KS 
patients and showed that 70% of them were relatives, forming one family with five affected 
individuals in two generations, and several smaller families with two first degree relatives with 
KS. We also showed that KS incidence was higher in the individuals originating from western 
and northeastern Finland compared to individuals originating from other parts of the country. 
In the second study, the genetic susceptibility of KS in the families that were identified in study I 
was examined. We mapped the shared chromosomal regions and performed whole genome and 
exome sequencing and identified 14 protein code altering candidate variants, among them a 
c.1337 C>T (p.Thr446Ile) variant in signal transducer and activator of transcription 4, (STAT4). 
The variant was not found from 242 Finnish genomes or 180 healthy regional control individuals. 
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We collected samples from the c.1337C>T variant carriers and showed that the activated T-cell 
populations of the carriers had decreased interferon gamma (IFN-γ) production. We studied the 
protein coding regions of STAT4 and related genes in the exomes sequenced from seven Finnish 
familial KS cases and identified a missense mutation p.His289Arg in chemokine (C-C motif) 
receptor 5 (gene/pseudogene) (CCR5), that segregated with the KS in the family with two 
affected siblings. We also studied the entire protein coding region of STAT4 from 13 additional 
familial KS cases and the STAT4 c.1337C>T site from 56 sporadic KS tumors, but did not find 
additional mutations. Although our results were not genetically validated, they suggest STAT4 as 
a KS predisposing gene. However, further genetic and functional validation is needed to claim 
causality. 
In study III, a Finnish family of four cousins with a rare subtype of Hodgkin lymphoma, nodular 
lymphocyte predominant Hodgkin lymphoma (NLPHL), was studied. To identify the genetic 
defect underlying the NLPHL susceptibility, we performed exome sequencing together with 
genome-wide linkage analysis and found a two base pair (bp) frameshift deletion (c.2437-
2438_delAG) in nuclear protein, ataxia-telangiectasia locus (NPAT) segregating with NLPHL in 
the family. The patients had a decreased expression of NPAT, measured from the blood. We 
studied NPAT from a large number of other patients with Hodgkin lymphoma, and identified a 
three bp in-frame deletion c. 2171-2173delCTT (p.Ser725del), which was shown to be more 
prevalent in cases than population matched controls (odds ratio 4.11, P=0.018), supporting the 
role of NPAT as a possible predisposition gene for NLPHL. 
A similar approach was used in study IV, where a Finnish family with five affected siblings with 
NF2-negative multiple intracranial meningiomas was scrutinized. By combining genome-wide 
linkage analysis and exome sequencing we identified a missense mutation c.367C>T 
(p.Arg123Cys) in suppressor of fused homolog (Drosophila) (SUFU) to segregate with the 
meningiomas in the family. We studied the tumors for loss of heterozygosity and found that all 
seven studied tumors had lost the wild-type allele, supporting the role of SUFU as a classic 
tumor-suppressor gene. We studied the effect of the mutation in vitro and in silico and showed 
that the mutated SUFU had lowered activity leading to dysregulated hedgehog signaling, most 
likely due to disrupted tertiary structure of the protein. We also studied the presence of additional 
SUFU mutations in a large set (n=162) of meningioma patients, but did not identify additional 
pathogenic mutations. The data indicates that, in addition to medulloblastomas, germline 
mutation in SUFU predisposes to meningiomas, particularly to multiple and intracranial types.  
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REVIEW OF THE LITERATURE 
1. Tumorigenesis 
Cell is the basic unit of all living organisms. The human body consists of about 3-4 × 1013 cells 
(Bianconi et al., 2013), representing hundreds of different cell types, that are all descendants of 
the fertilized egg. Most of the cells in the adult human body are carefully programmed to serve a 
defined function and only in collaboration with one another. For maintaining tissue and to carry 
out functions such as wound healing or menstrual cycle, cells need to retain the ability to 
replicate and renew throughout the lifetime of an individual. Although the replication machinery 
is deliberately controlled, it becomes time to time corrupted, which can lead to uncontrolled cell 
division and growth and eventually to a formation of an atypical mass of cells, a tumor. 
Tumors can be divided into benign and malignant based on their ability to invade the tissues 
locally, and seed cells to other tissues and organs, that is, to metastasize. Compared to malignant 
tumors, benign tumors generally grow slower, resemble more the tissue they derive from and are 
rarely life threathening to their host. However, they can cause serious health problems by 
pressing the nearby tissues and anatomical structures, inducing for example neurological deficits 
and/or over-secretion of hormones.  
A common concept in tumorigenesis is that malignant tumors develop from benign predecessors. 
This has been well-established especially in tumors that arise from epithelial cells, such as 
colorectal cancer (Fearon and Vogelstein, 1990). The great majority (~85%) of colorectal cancers 
are estimated to develop from a benign adenomatous polyp and progress into a mature colorectal 
cancer through several intermediate forms, in a process called the adenoma-carcinoma sequence 
(Fearon and Vogelstein, 1990; Vogelstein et al., 1988). Some benign tumors, such as leiomyomas 
and meningiomas, however, rarely advance to malignant tumors (Lall et al., 2013; van Meurs et 
al., 2012).  
The development of a tumor is a lengthy process that can take years or even decades, and it 
involves reprogramming of several aspects of the tumor forming cells. A landmark paper by 
Douglas Hanahan and Robert A. Weinberg (2000) described the essential biological features, ‘the 
hallmarks of cancer’ (I-VI, Box 1), that a cell has to obtain in order to initiate cancer. A decade 
later the authors complemented the list with two ‘emerging hallmarks’ (VII and VIII, Box 1) that 
are conceivably relevant to tumorigenesis (Hanahan and Weinberg, 2011). ‘Genome instability 
and mutation’ as well as ‘tumor promoting inflammation’ were suggested to act as facilitators for 
gaining the biological features needed for the tumor development (Hanahan and Weinberg, 2000; 
Hanahan and Weinberg, 2011). Of the eight ‘hallmarks of cancer’, all others are applicable to 
benign and malignant tumors except VI (the ability to invade nearby tissues and seed distant 
metastasis), which is applicable only to malignant tumors. 
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Box 1. The hallmarks of cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011) 
 
I ‘Self-sufficiency in growth signals’ 
Growth inducing signals are required for normal cell proliferation. One capability that tumor cells have acquired is 
that they are no longer dependent on the outside growth signals. Dividing tumor cells either signal the neighboring 
cells to produce growth signals, learn to produce an excess of these themselves, or change their behavior as if they 
would be present all the time.  
 
II ‘Insensitivity to anti-growth signals’ 
In addition to the growth inducing signals, the environment of a normal cell contains multiple growth inhibitory 
signals. To prosper, a tumor cell needs to acquire ways to overcome growth inhibitory signals.  
 
III ‘Evading apoptosis”’ 
When normal cell is under an unusual stress caused by, for example, excessive DNA damage or lack of nutrients 
and/or oxygen, the cell is directed to undergo programmed cell death, apoptosis. In order to grow, a tumor cell 
needs to acquire means to eliminate signals directing it to various cellular death pathways. 
 
IV ‘Limitless replicative potential’ 
The number of cell divisions is by implication measured by the shortening of the telomeres. This is how the cell 
keeps track of its growth and the number of divisions it has gone through. Most of the normal cells can undergo 
only a limited number of cell divisions after which they stop dividing and reach irreversible quiescent state called 
senescence. In order to divide endlessly, tumor cell needs to learn to manipulate its time keeping machine, the 
telomeres. 
 
V ‘Sustained angiogenesis’ 
To obtain enough oxygen and nutrition and to get rid of metabolic waste and carbon dioxide, cells have to be 
located within <1 mm from a capillary blood vessel. The same holds for tumor cells. Thus expanding tumor needs 
to be able to induce growth of new vasculature.  
 
VI ‘Tissue invasion & metastasis’ 
The capability of a tumor cell to invade and metastasize requires abilities to escape the primary tumor mass as well 
as colonize new ground. Thus the process of invasion and metastasis is considered to require large scale 
reprogramming of many cellular functions, especially those that have to do with cell-cell adhesion, extracellular 
matrix degradation and motility.      
 
VII ‘Reprogramming Energy Metabolism’ 
To support proliferation, tumor cells adjust their energy supply. This can be done by reprogramming glucose 
metabolism, increasing the number of glucose transporters on the cell surface or, relying on alternative metabolic 
pathways and/or energy sources. Many tumors change to glycolysis even in normal oxygen conditions. Despite the 
fact that, this is not the most cost-effective way to produce energy, it allows tumor cells to supply glycolytic 
intermediates to cellular pathways that are needed to build new cells.  
 
VIII ‘Evading immune destruction’ 
The theory of immune surveillance suggests that the immune system constantly monitors the human body for 
abnormal cells. Based on this idea, arising tumors have somehow managed to avoid the detection and destruction 
by the immune system. The important role of immunological monitoring can be seen, for example, in the increased 
burden of tumors in immunocompromised individuals.   
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Two models are commonly proposed to explain tumorous growth (Beck and Blanpain, 2013; 
Weinberg, 2013). The stochastic model is based on the idea that each cell is equipotent to gain 
replicative advantage or differentiate. In this model, any cell clone with growth advantage forms 
a proliferating clonal population (Beck and Blanpain, 2013; Weinberg, 2013). The other model, 
the tumor stem cell model, is based on the idea that a higher organization exists in the tumors, 
much like in the normal tissues. In this model, only a small subset of cells, called the tumor stem 
cells, are able to proliferate and drive the tumor development (Reya et al., 2001; Dick, 2008; 
Beck and Blanpain, 2013). 
2. Human genome 
With few exceptions, all human cells contain the same set of genetic material, the human genome. 
It is composed of deoxyribonucleic acid (DNA) and organized into 22 pairs of linear autosomal 
chromosomes, two linear sex chromosomes and a small circular mitochondrial genome. The 
linear chromosomes are deposited in the cell nuclei, and the mitochondrial genome is stored 
within the mitochondria, which reside in the cytoplasm.  
The first drafts of the human genome sequence were published in 2001 (Lander et al., 2001; 
Venter et al., 2001), followed by the first complete version of the human genome sequence in 
2004 (International Human Genome Sequencing Consortium, 2004). Since 2004, the human 
genome sequence has been corrected and improved, and today probably the most up-to-date 
human reference genome sequence is upheld and updated by Genome Reference Concortia. The 
human genome reference assembly, most in use currently, contains about 3.3 billion nucleotides, 
or DNA monomers (Genome Reference Consortium, Human Genome Assembly GRCh37, 
released in March 2009 http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/human/, 
latest update GRCh37.p13, June 2013). According to the Encyclopedia of genes and gene 
variants (the GENCODE project), the reference human genome encodes 57 820 genes of which 
20 345 translate proteins, 14 206 are pseudogenes, 13 870 transcribe long non-coding RNAs, 
9013 transcribe small non-coding RNAs and 386 encode protein coding segments of the 
immunoglobulin and T-cell receptor gene segments (The GENCODE project, version 19 July 
2013 freeze, GRCh37, http://www.gencodegenes.org/stats.html).  
The coding parts of the human reference genome constitute less than 3% of its entire length 
(Alexander et al., 2010) and the rest is composed of so called non-coding regions, which were 
historically considered as “junk DNA”, with little or no biological function. During the last few 
years, however, increasing numbers of non-coding sequence elements, relevant for example in 
the regulation of gene expression or DNA replication, have been annotated (Maston et al., 2006; 
Harmston and Lenhard, 2013). The international Encyclopedia of DNA Elements (ENCODE) 
project recently reported a biological function for more than 80% of the human genome 
(ENCODE Project Consortium et al., 2012). Although ENCODE’s data interpretation and 
definition of the biological function has faced a lot of criticism (Doolittle, 2013; Eddy, 2012; 
Graur et al., 2013; Niu and Jiang, 2013), it is evident that, in addition to the protein coding genes, 
biologically relevant sequences are widely spread throughout the non-coding parts of the human 
genome.   
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Each individual human genome contains a significant amount of variation compared to each other 
or to the human reference genome. Several international large-scale projects, such as the 
International HapMap Project (International HapMap Consortium, 2003; International HapMap 
Consortium, 2005; International HapMap Consortium et al., 2007) and more recently the 1000 
Genomes Project (1000 Genomes Project Consortium et al., 2012), have been carried out to 
elucidate the genetic variation in individual genomes and different populations. In 2012, the 1000 
Genomes Project Consortium published results on low-coverage genomes, high-coverage exomes 
and dense single nucleotide polymorphism (SNP) genotypes of 1092 individuals representing 14 
different populations, including 93 Finnish individuals. They reported altogether 38 million SNPs, 
1.4 million short insertions or deletions, and over 14 000 larger deletions (1000 Genomes Project 
Consortium et al., 2012). Furthermore, they described that on average each individual genome 
contains over 3 million SNPs (on average 1 SNP in every 1000 nucleotides) including 2500 
protein coding variants and 150 protein function disrupting variants (1000 Genomes Project 
Consortium et al., 2012). Most of these are shared by many individuals and multiple populations, 
but some are rare and present only in a certain population or an individual. Over half (53%) of the 
rare variants (minor allele frequency; MAF <0.5%) reported by the 1000 Genomes Project 
Consortium were present only in one population (1000 Genomes Project Consortium et al., 2012). 
In addition to SNPs small insertions and deletions, human genomes vary on a DNA copy number 
level (Feuk et al., 2006). Copy number variants (CNVs) represent gains and losses of larger areas 
of the genomic DNA, ranging from one kilobase (kb) to several megabases in size. The curated 
database of genomic variants includes currently more than 2.5 million CNVs (the Database of 
Genomic Variants, http://dgv.tcag.ca/dgv/app/home, accessed 25
th
 of April 2014). It has been 
estimated that each individual harbors on average 200 CNVs, majority of which are 1-10 kb in 
size (Kidd et al., 2008, and the Database of Genomic Variants).  
Individual human genomes vary also in their contents of sequential nucleotide repeats, called 
micro- and minisatellites. Although this type of variation is usually considered neutral, it is 
known to cause for example certain neurological diseases (Brouwer et al., 2009). Almost half of 
the human genome is also occupied by transposons and transposon-like elements (Mills et al., 
2007). Transposons are in principle mobile elements that can produce variation in the human 
genome by copying and pasting DNA pieces from one place to another. The only transposons 
that are currently known to be active in the human genome are retrotransposable elements, 
including long interspersed elements, short interspersed elements, and SVA (SINE/VNTR/Alu) 
elements (Callinan and Batzer, 2006; Mills et al., 2007), but their contribution to genetic 
variation is yet to be fully elucidated.  
The earliest settlements in Finland dates back to some 10 000 years, but the Finnish population is 
generally considered to be initiated by two major migratory waves 4000 and 2000 years ago 
(Jakkula et al., 2008). A third major migratory wave, inhabiting the geographically wide areas of 
the northern and eastern Finland, took place in the 16
th
 century. During this period isolated 
villages were established by a small number of settlers generating multiple genetically distinct 
isolated subpopulations (Jakkula et al., 2008). The early founder effects together with the more 
recent bottle necks have resulted in the decreased genetic diversity and increased number of rare 
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and loss-of-function variants of Finnish population (1000 Genomes Project Consortium et al., 
2012; Jakkula et al., 2008; Lim et al., 2014).  
 
3. Tumor genome 
The idea that tumors develop due to genetic defects dates back to the times of a pioneering 
German biologist Theodor Boveri (1862-1915). He studied dividing sea urchin eggs and noticed 
that the embryonic development was successful only when the genetic material was correctly 
divided between the two daughter cells. This led him to postulate that human tumors might 
similarly be caused by unequal segregation of the genetic material (Boveri, 1902). Boveri went 
on with his ideas, and published later a theoretical essay hypothesizing several aspects of 
tumorigenesis, that were only later proven experimentally, including clonal evolution, 
development of malignant tumors from benign predecessors, presence of growth promoting and 
inhibiting factors (genes) in the chromosomes (Boveri, 1914; Boveri, 2008).  
Since the times of Boveri, the developments made in microscopy and molecular biology, 
especially the discovery of the DNA structure (Avery et al., 1944; Watson and Crick, 1953a; 
Watson and Crick, 1953b) and the genetic code (Crick et al., 1961), have led to our current 
understanding, that tumors are genetic diseases caused by genomic alterations, or mutations 
(Nowell, 1976; Hanahan and Weinberg, 2011), which can be caused by endogenous or 
exogenous carcinogens or be produced by erroneous DNA replication. Mutations that affect the 
tumor genomes range from subtle nucleotide level alterations, including substitutions and small 
insertions and deletions, to a chromosome level alterations, including translocations, inversions, 
deletions or amplifications. Additionally, whole chromosomes can be lost or gained (aneuploidy) 
and even the entire set of chromosomes can be multiplied (polyploidy).  
Other central flaws affecting the tumor genomes include epigenetic alterations that do not change 
the actual DNA sequence, but may lead to altered gene expression and thus assist the developing 
tumor to acquire novel profitable traits. From the epigenetic modifications affecting tumors, 
DNA methylation and histone modifications are probably the best studied. Methylation is a 
simple covalent DNA modification that occurs generally at sites of CpG nucleotides. Both 
hypomethylation and hypermethylation, especially at the promoter regions of tumor associated 
genes, are commonly observed in the tumor genomes (Choi and Lee, 2013). Hypomethylation 
usually leads to an increase and hypermethylation to a decrease of gene expression (Choi and Lee, 
2013). Histones are proteins that are used to pack the human genome. They are regulated by post-
translational modifications, and when this is done incorrectly it can also lead to altered gene 
expression (Choi and Lee, 2013). 
The overall number and types of mutations varies greatly among different tumor types and 
between tumors. The highest numbers of mutations, up to thousands, are seen in tumors with 
defective DNA repair machinery, including microsatellite unstable colorectal or gastric cancers 
(Gryfe and Gallinger, 2001) and colorectal cancers harboring mutations in the proofreading 
domains of DNA polymerases POLE and POLD1 (Cancer Genome Atlas Network, 2012; Palles 
et al., 2013). High numbers of mutations, on average 200 per tumor, are also observed in tumors 
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with a potent exogenous mutagen, such as tobacco smoke exposed lung cancers and UV-exposed 
melanomas (Pfeifer, 2010; Vogelstein et al., 2013). In tumors originating from rapidly renewing 
tissues, such as those deriving from epithelium, the patient age has been shown to directly 
correlate with the number of mutations (Tomasetti et al., 2013). Least mutations are observed in 
certain benign tumors, pediatric cancers, and leukemias (Mardis et al., 2009; Francis et al., 2013; 
Mehine et al., 2013).   
The recent application of high-throughput sequencing methods has revolutionized the field of 
tumor genomics enabling very detailed and precise characterization of the mutational profiles of 
different tumors. In addition to the sequencing studies conducted in separate research laboratories 
and centers, several large-scale international projects have been put together to elucidate the 
mutational landscapes of many human tumors. Probably the largest of these is the International 
Cancer Genome Consortium (ICGC) that aims to catalogue the mutations of the 50 most common 
tumor types and release the data for public use (https://www.icgc.org/ and International Cancer 
Genome Consortium et al., 2010). Currently the ICGC database includes genomic sequences 
from 42 projects representing 18 different tumor primary sites from over 10 000 individuals 
(ICGC Data release 15.1, February 12, 2014, http://dcc.icgc.org/).  
The novel sequencing methods have also provided a more detailed description of the mutational 
processes present in the tumors. In a recent study, 21 distinct ‘mutational signatures’ were 
identified from the genomic and exomic sequences of 7042 primary tumors deriving from 30 
different tumor types (Alexandrov et al., 2013). In addition to the already established mutational 
signatures, like those induced by carcinogens in tobacco, UV-light, and defective DNA repair 
machinery, novel signatures associated with, for example, patient age or usage of certain 
anticancer drugs were described. A few signatures remain yet to be explained (Alexandrov et al., 
2013) and some possibly yet to found.  
Novel mutational phenomena have also been recently described. Chromotripsis, which was 
initially found as a frequent event in the genomes of malignant bone tumors (Stephens et al., 
2011), is a complex genomic rearrangement caused by chaotic shattering of one or few 
chromosome arms into tens to hundreds of pieces followed by a stochastic reassembly (Stephens 
et al., 2011). Chromotripsis has been associated with advanced stage and poor prognosis 
(Forment et al., 2012), but similar chromosomal alterations have later been shown in benign 
tumors (Mehine et al., 2013; Parker et al., 2014). Chromotripsis has also been reported to affect 
germline genomes and it was recently identified as the underlying mechanistic cause of specific 
Robertsonian translocation rob(15;21)(q10;q10)c, which is known to predispose to childhood 
acute lymphoblastic leukemia (Li et al., 2014).  
Kataegis, which is defined by a regional hypermutation of long stretches of DNA (kilobases in 
length), was originally identified from a subset of breast cancer genomes (Nik-Zainal et al., 2012). 
It has also been subsequently found from ovarian cancer and multiple myeloma genomes (Bolli et 
al., 2014; Hoogstraat et al., 2014). The mutations in kataegis commonly affect the same parental 
chromosome, are preferably C>T transitions, and co-localize with chromosomal rearrangements. 
Although the mechanism causing Kataegis is not yet well understood, APOBEC family of 
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cytidine deaminases have been suggested to play a role (Lada et al., 2012; Nik-Zainal et al., 
2012).  
3.1 Driver mutations and genes  
Genetic and epigenetic changes that affect the tumor genomes can be classified as ‘drivers’ or 
‘passengers’ (Thiagalingam et al., 1996). Driver mutations are mutations or epigenetic changes 
that confer a selective growth advantage to the cell whereas passenger mutations are bystanders 
and reflect the stochastic mutational process present in the tumors (Thiagalingam et al., 1996). 
Tumors have been estimated to contain one to eight driver mutations, each of which most likely 
conferring only a small selective growth advantage (Armitage and Doll, 2004; Bozic et al., 2010; 
Welch et al., 2012; Vogelstein et al., 2013). The rest of the mutations are passengers.  
Driver mutations occur in a fraction of genes that can be called as ‘driver genes’. These are 
normal genes that in mutated form can promote tumorigenesis (Vogelstein et al., 2013). Driver 
genes can further be classified into proto-oncogenes and tumor suppressor genes. Proto-
oncogenes are normal cellular genes that encode proteins involved in the cell growth, cell 
replication, inhibition of cell differentiation, and regulation of cell death (Croce, 2008). Proto-
oncogenes are activated by overexpression or gain-of-function mutations after which they are 
called oncogenes. At the cellular level, oncogenes are dominant, which means that usually only 
one of the two gene copies needs to be mutated to stimulate tumorigenic effects. Common 
oncogenic mutations are simple base substitutions changing a critical amino acid into another 
during protein translation, but oncogenes can also become activated by a translocation or 
amplification that leads to overexpression of the proto-oncogene. Well-established proto-
oncogenes encode for example growth factors (such as EGF and PDGFs) and growth factor 
receptors (EGFRs and PDGFRs), chromatin re-modelers (KMT2A), signal transducers (BRAF 
and KRAS), transcription factors (MYC), and apoptosis regulators (BCL2).  
Tumor suppressor genes normally function in growth repression, by either controlling cell 
proliferation or promoting apoptosis (Sherr, 2004). Mutations responsible for the tumorigenic 
actions of tumor suppressor genes are loss-of-function mutations and typically both copies of the 
tumor suppressor gene need to be affected for the tumorigenic effect. Mutations that commonly 
affect tumor suppressor genes are small insertions and deletions breaking the reading, nucleotide 
substitutions that cause a translation of a premature stop-codon, or mutations affecting mRNA 
splicing. However, they can also be larger chromosomal deletions that delete the tumor 
suppressor gene partially or entirely. Mutations found in tumor suppressor genes are usually not 
clustered and are spread across the length of the gene (Vogelstein et al., 2013).  
Tumor suppressor genes can be classified into gatekeepers, caretakers, (Kinzler and Vogelstein, 
1997), and landscapers (Kinzler and Vogelstein, 1998). Gatekeepers are the most classical types 
of tumor suppressor genes, and their normal functions include inhibition of cell growth and 
proliferation. Many gatekeeper genes have been identified as the underlying causal genes behind 
well-established cancer susceptibility syndromes, such as Neurofibromatosis, type I (MIM 
16220), as well as Li-Fraumeni (MIM 151623) and Von Hippel-Lindau (MIM 19330) syndromes. 
Caretakers on the other hand are stability genes that are responsible, for example, for maintaining 
16 
 
DNA intact and mitotic recombination. An inactivated caretaker has an indirect effect on 
tumorigenesis and it can, for example, increase the general mutation rate of the genome and 
thereby increase the chances of a mutation in another driver gene. Examples of caretakers are 
MLH1 and MSH2, which encoding proteins central in the DNA mismatch repair machinery, and 
BRCA1 and BRCA2, which encode proteins that repair DNA double strand breaks. Landscapers, 
such as SMAD4, remodel the tumor surroundings more amenable for growth. 
Concepts of dominant negativity and haploinsufficiency are tightly linked to tumor suppressor 
genes (Santarosa and Ashworth, 2004; Payne and Kemp, 2005). Dominant negative mutations 
affect especially polymeric molecules, such as TP53, ATM, and CDKN1A (Payne and Kemp, 
2005). The mutated protein product is not fully functional, but it is functional enough to interact 
with the wild-type protein product, thus impairing the actions of the entire polymeric protein. 
Haploinsufficiency means that inactivation of only one copy of a tumor suppressor gene has 
already a positive effect to tumor growth (Santarosa and Ashworth, 2004). Some studies have 
suggested that tumor suppressor genes and proto-oncogenes cluster in certain areas of the genome 
and that larger hemizygous chromosomal alterations that either delete several tumor suppressor 
genes or amplify several proto-oncogenes may introduce a selective growth advantage for the cell 
(Solimini et al., 2012; Xue et al., 2012).     
4. Inherited susceptibility to tumors 
Although most tumors arise in isolated patients, familial aggregation of tumors has been long 
acknowledged. One of the earliest reports of familial clustering of tumors was published by Paul 
Broca in 1866, who described his wife’s family with 15 members with breast cancer (Broca, 
1866). Majority of common cancers have been shown to display high concordance in 
monozygotic twins, compared to dizygotic twins or siblings, indicating importance of the shared 
genetic factors (Lichtenstein et al., 2000). The relevance of the shared genetic factors has also 
been emphasized by a number of family- and population-based studies. Large population-based 
studies have been conducted, for example, using Utah Population and Cancer Registry Database, 
the Swedish Family-Cancer Database, or Icelandic Cancer Registry and the genealogic database. 
These studies have collectively demonstrated that most of the common tumor types display 
increased risk in first-degree relatives and also beyond the nuclear family (Cannon-Albright et al., 
1994; Goldgar et al., 1994; Vaittinen and Hemminki, 1999; Dong and Hemminki, 2001; Czene et 
al., 2002; Amundadottir et al., 2004; Albright et al., 2012). In addition to familial aggregation of 
specific cancer types within families, marked coaggregation of different cancers has also been 
reported (Thomas et al., 1999). 
In addition to the genetic factors, there are also a variety of environmental factors that may be 
shared within famileis, and a fraction of familial cancers is likely to be explained by these 
(Hemminki et al., 2006). For example, increased risk for lung and stomach cancers has been 
reported in spouses of lung and stomach cancer patients, emphasizing the role of shared 
environment (Hemminki et al., 2001; Hemminki and Jiang, 2002; Amundadottir et al., 2004). 
Also certain childhood cancers, such as acute lymphoblastic leukemia, which show high 
concordance in monozygotic twins, have been shown to have non-constitutional, prenatal causes 
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(Ford et al., 1993; Wiemels et al., 1999). Nonetheless, even in these cases the individual genetic 
make-up most likely plays a central role, since it influences the ability of an individual to deal 
with the environmental exposures.  
Inherited genetic factors that predispose to tumors can be roughly divided into three categories: 
rare high risk variants, rare moderate risk variants and common low risk variants. The rare high 
risk variants are present in the population with minor allele frequency (MAF) lower than 0.1%, 
and the carriers of these are highly likely to develop a tumor (odds ratio ≥10.0). The rare 
moderate risk variants are present in less than 2% of the population and individuals carrying these 
variants are at >2 fold risk of developing a given tumor. Common low-risk alleles are frequent, 
present in >10% of the population, and confer a small risk for the individual (odds ratio <1.5) 
(Fletcher and Houlston, 2010).  
4.1 Rare high risk variants 
In general it is considered that 5-10% of tumors arise in individuals with hereditary cancer 
syndromes, caused by rare high risk variants in tumor predisposition genes (Nagy et al., 2004). 
Examples of well-characterized hereditary cancer syndromes are, for example, hereditary breast 
and ovarian cancer syndrome (MIM #604370), Lynch syndrome (MIM #120435), Von Hippel 
Lindau syndrome (MIM #193300) and Li Fraumeni syndrome (MIM #151623). Clinical evidence 
for the presence of hereditary cancer syndrome include young age at onset, presence of bilateral 
disease, multiple primary tumors, and a family history with multiple family members affected by 
the same tumor type. Hereditary cancer syndromes are also often characterized by other non-
tumor related clinical manifestations. These may be even more frequent in the family than the 
tumors, and they are often very important cues for the clinical diagnosis (Rahman, 2014). The 
most common non-tumor related clinical manifestations are various skin lesions. Also many 
neurological, dysmorphic, and skeletal features, such as microcephaly, macrocephaly, short 
stature, and developmental delay, are encountered in the carriers of the high risk alleles (Rahman, 
2014).  
In the beginning of the 20
th
 century, multiple large families with clear inheritance of hereditary 
cancer susceptibility syndromes were described by clinicians such as Aldred S. Warthin (Warthin, 
1929), Johannes Peutz (Peutz, 1921), and Harold Jeghers (Jeghers et al., 1949), but it was not 
until 1987, when the first gene, RB1, was identified as the underlying gene in childhood 
retinoblastoma predisposition (Fung et al., 1987). This finding was facilitated by the ‘two-hit 
hypothesis’ proposed by Alfred Knudson in 1971 (Knudson, 1971). Knudson studied the kinetics 
of familial and sporadic childhood retinoblastoma and noticed that the familial cases usually had 
earlier age at onset and their tumors affected more often both eyes. He proposed that 
retinoblastoma was caused by a single gene defect and that the development of retinoblastoma 
required both alleles of the gene to be inactivated. He suggested that in the familial cases the 
other allele of the gene is inherited as defective and the other is inactivated by somatic mutation 
later during life. In the sporadic cases, both alleles needed to be inactivated by de novo mutations 
(Knudson, 1971). After the discovery of the RB1, more than 100 rare high risk tumor 
predisposition genes have been identified (Marsh and Zori, 2002; Genuardi, 2004; Rahman, 
2014). 
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The high risk tumor predisposition genes are most often tumor suppressor genes and follow 
Knudson’s ‘two-hit hypothesis’. Majority of them are located in autosomes and inherited 
dominantly, although recessive, X-linked and Y-linked forms also exist (Rahman, 2014). In 
addition, 16 high risk tumor predisposing genes have been described to display both dominant 
and recessive inheritance. Some of these, such as BRCA2, MLH1, MSH2, and MHS6 have been 
associated with adult onset cancers when inherited dominantly and childhood cancer when 
inherited recessively (Rahman, 2014). A small minority of the high risk cancer susceptibility 
genes harbor also oncogenic gain-of-function mutations (Rahman, 2014). Examples of such 
include RET, KIT, and ALK (Rahman, 2014). Clinical symptoms are present in majority of the 
patients carrying high risk tumor predisposing alleles by the age of 70 (Nagy et al., 2004). 
However, due to factors such as phenotypic variability and age related penetrance, some 
individuals carrying high risk tumor predisposing alleles do not show complete penetrance. 
4.2 Rare moderate risk variants 
A proportion of familial aggregation of common cancers has been detected to result from rare 
variants with incomplete penetrance conferring moderate risk to their carriers. These variants 
have been studied especially in breast cancer, where relatively rare alleles of different members 
of the DNA-damage response pathway, namely CHEK2 (Meijers-Heijboer et al., 2002; 
Vahteristo et al., 2002), PALB2 (Rahman et al., 2007), ATM, (Renwick et al., 2006), NBS1 
(Steffen et al., 2006), and BRIP1 (Seal et al., 2006), have been identified to increase the risk of 
breast cancer 2-9 fold (Hollestelle et al., 2010). In addition to breast cancer, inactivating 
mutations in BRIP1 have been reported to confer moderate risk for ovarian cancer (Rafnar et al., 
2011), and a rare missense mutation in HOXB13 has been reported to confer a moderate risk for 
prostate cancer (Xu et al., 2013). A few examples exist, where a specific mutation in a well-
established high risk cancer predisposition gene, has been associated with moderate risk. One 
example is the p.Glu1317Gln missense mutation in APC found in the Ashkenazi Jews (Laken et 
al., 1997; Liang et al., 2013). The presence of the rare moderate risk variants varies in 
populations, which makes it hard to validate the results and evaluate the actual risk (Lalloo and 
Evans, 2012). 
4.3 Common low risk variants 
The common disease-common variant hypothesis predicts that genetic variants that are frequent 
in the population affect the individual risk of getting a common disease (Risch and Merikangas, 
1996). Common variants associated with common diseases can be studied by association studies 
that compare the frequencies of alleles in sets of unrelated cases and controls. Before 
development of the genome-wide genotyping methods, association studies were conducted using 
only a restricted number of common polymorphisms in selected candidate genes or pathways 
(Easton and Eeles, 2008; Chung and Chanock, 2011). Today, the candidate gene based methods 
have been largerly replaced with genome-wide association studies (GWAS) (Hirschhorn and 
Daly, 2005), which measure the association of the disease with usuallu hundreds of thousands of 
markers distributed throughout the genome.  
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To date, about 400 different cancer-associated common low risk variants, or loci, have been 
identified through GWAS studies (Hindorff et al., 2009; Rahman, 2014). The overall risk of an 
individual associating locus or SNP is generally small, in the order of 1.1-1.4 fold (Chung and 
Chanock, 2011). However, the combinatorial effect of multiple common low risk alleles may be 
substantially larger (Zheng et al., 2008).  
A major limitation with the GWAS is that the associated genomic markers are only landmarks of 
the associated loci, and many times the factors that actually cause the predisposition are difficult 
to identify. The underlying causal mechanisms have been determined for only a very small 
number of associated loci (Edwards et al., 2013). Majority of the common low risk loci are 
associated with increased risk for one specific tumor type, but a few multi-cancer loci exist that 
are associated with multiple tumors, including the region flanking the MYC oncogene at 8q24, the 
TERT-CLPTM1L containing region at 5p15.33, and the ~400kb region at 11q13 (Chung and 
Chanock, 2011). Surprisingly few are located within high or moderate risk cancer genes, 
suggesting that the mechanisms underlying the predisposition caused by rare high and moderate 
risk alleles and common low risk alleles are in large part different (Rahman, 2014).  
5. Infectious causes of cancer  
Approximately 16-20% of cancers are estimated to be induced by infectious agents (Bouvard et 
al., 2009; de Martel et al., 2012). The contribution of the infectious agents to the entire cancer 
burden varies widely in different areas of the world, the biggest burden being in the low-resource 
countries where the infectious conditions are more widespread (de Martel et al., 2012; IARC 
Working group, 2012a).  
International Agency for Research on Cancer (IARC) Monographs programme has classified one 
bacterial (Helicobacter pylori [H pylori]), seven viral (Epstein-Barr virus [EBV], human T-cell 
lymphotropic virus type 1 [HTLV-1], human papilloma virus [HPV], human herpesvirus 8 
[HHV8], hepatits B and C viruses [HBV and HCV], and human immunodeficiency virus-1 [HIV-
1]) and three parasitic infections (Opisthorchis viverrini, Clonorchis sinensis, and Schitsosoma 
haematobium) as the Group 1 Biological carcinogenic agents to humans (Table 1). These agents 
are estimated to cause 2 million new cancers per year and more than 90% of these are caused by 
the top four agents, namely HBV and HCV, HPV and H pylori, (de Martel et al., 2012, Table 1). 
Mechanisms of how infectious agents can promote tumorigenesis include induction of chronic 
inflammation and reprogramming of the host inflammatory and infected cells to produce tumor 
growth enhancing molecules, which can further result to the production of carcinogenic agents 
(for example reactive oxygen species) and/or changes in the tumor microenvironment (Table 2). 
Four viral agents, HTLV-1, EBV, HHV8, and HPV, have also been established to have direct 
carcinogenic effects, meaning that they can in vitro immortalize cultured cells and express 
multiple oncogenes that interact with the host proteins, which in turn lead to alterations in the cell 
cycle control (Table 2). The genome of these agents is entirely or partly present in every cell in 
the tumor. Infectious carcinogenic agents can also cause immunosuppression. The best example 
of this is possibly HIV-1 infection which predisposes the affected individuals to opportunistic 
infections, including those with carcinogenic effects (Table 2).   
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Table 1. Group 1 biological carcinogenic agents assessed by the IARC Monograph Working 
Group 
Infectious agent Associated cancers
*
 Infection attributable 
cancers per year
**
 
Helicobacter  pylori Gastric cancer, low-grade B-cell mucosa-
associated lymphoid tissue (MALT) 
gastric lymphoma 
 
660 000 (32.5%) 
Human papillomavirus 
(HPV) 
Carcinoma of cervix, vulva, vagina, 
penis, anus, oral cavity, oropharynx and 
tonsil 
 
610 000 (30.0%) 
Hepatitis B and C virus 
(HBV and HBC) 
Hepatocellular carcinoma, non-Hodgkin 
lymphoma; HBC 
 
600 000 (29.5%) 
Ebstein-Barr virus 
(EBV) 
 
Burkitt lymphoma, nasopharyngeal 
carcinoma,immune-suppression-related 
non-Hodgkin lymphoma, Hodgkin 
lymphoma, T-cell and NK-cell lymphoma 
(nasal type) 
 
110 000 (5.4%) 
Human Herpesvirus 8 
(HHV8)   
Kaposi sarcoma, primary effusion 
lymphoma 
 
 
43 000 (2.1%) 
Schitsosoma 
haematobium 
Urinary bladder cancer 6000 (0.3%) 
 
Human T-cell 
lymphotropic virus type 1 
(HTLV-1) 
 
 
Adult T-cell lymphoblastic leukemia and 
lymphoma 
 
2100 (0.1%) 
Opisthorchis viverrini 
and Clonorchis sinensis 
Cholangiocarcinoma, hepatocellular 
carcinoma 
 
 
2000 (0.1%) 
Human 
Immunodeficiency virus-
1 (HIV-1) 
Viral cancers, including: Kaposi sarcoma; 
KSHV, non-Hodgkin lymphoma; EBV 
related and non-related, Hodgkin 
lymphoma; EBV, Carcinoma of the 
cervix, anus, conjunctiva; HPV 
Not determined 
Total  2 000 0000 (100%) 
*
For which there is sufficient evidence in humans (IARC Working group, 2012a);
**
Numbers describes 
those of 2008 and are obtained from de Martel et al., 2012.  
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Table 2. Properties of the human carcinogenic viruses 
Virus Genome Host 
genome 
integration 
Infection related 
symptoms 
 
Mechanistic effects 
 
EBV DNA no Asymptomatic, 
respiratory illnesses and 
mononucleosis 
 
Cell proliferation, inhibition 
of apoptosis, genomic 
instability, cell migration 
 
HPV DNA yes Asymptomatic, 
genital warts 
 
Cell immortalization, 
genomic instability, inhibition 
of DNA damage response, 
anti-apoptotic activity 
 
HBV DNA yes Asymptomatic, 
acute hepatitis B 
 
Inflammation, liver chirrosis, 
liver fibrosis 
 
HCV RNA nd Asymptomatic 
 
Immortalization and 
transformation of T cells 
 
HTLV-1 RNA yes Asymptomatic, 
Myelopathy/ 
Tropical Spastic 
Paraparesis, 
inflammation of eye, 
joints, muscles, lung and 
skin 
 
Cell proliferation, inhibition 
of apoptosis, genomic 
instability, cell migration 
 
HHV8 DNA no Asymptomatic Cell proliferation, inhibition 
of apoptosis, genomic 
instability, cell migration 
 
HIV-1 RNA yes Immunosuppression Immunosuppression (indirect 
effect) 
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6. Identification of rare high risk tumor susceptibility genes 
Majority of the currently known rare high risk tumor susceptibility genes have been discovered 
by positional cloning, which means that the gene is identified based on its genomic location, 
without prior hypothesis of its biological function. The strategy that has been used the most in the 
identification of rare high risk tumor susceptibility genes is genome-wide linkage analysis, which 
is a family based statistical method to trace disease-associated genomic markers (Rahman, 2014). 
In addition, some tumor susceptibility genes have been successfully identified through candidate-
gene based approaches. Screening of candicate genes based on their functional similarity to 
known tumor susceptibility genes has been used to identify novel susceptibility genes, such as 
PMS6, MSH6, SDHD, and SDH5 (Nicolaides et al., 1994; Miyaki et al., 1997; Niemann and 
Muller, 2000; Hao et al., 2009). Another advantageous candidate-based approach has been to 
explore genes associated with distinct cellular susceptibility phenotypes, such as DNA repair 
defects (Nichols et al., 1996; Sijbers et al., 1996) or mosaicism (Hanks et al., 2004). Also a small 
number of tumor susceptibility genes, including TP53, KIT, and SUFU have been identified 
because they are frequently somatically mutated in cancers (Malkin et al., 1990; Nishida et al., 
1998; Taylor et al., 2002). More recently, genome-wide mutation analyses using high-throughput 
sequencing either alone or in combination with linkage analysis have proven very powerful in the 
discovery of novel high risk tumor susceptibility genes (Comino-Mendez et al., 2011; Testa et 
al., 2011; Smith et al., 2013).  
6.1 Linkage analysis 
Linkage analysis is based on the concept that chromosomal loci that are physically close to each 
other are linked and are usually inherited together and are only rarely separated by recombination 
during meiosis. On the contrary, when two loci are far apart, for example in different 
chromosomes or in the opposite ends of the chromosome, recombination is likely to happen and 
the two loci are inherited independently (Pulst, 1999). Meiotic recombinations are not evenly 
spread across the human genome, and they tend to cluster in so called recombination hot spots 
(Kauppi et al., 2004; Paigen and Petkov, 2010). The observed portion of recombinations, that is 
recombination fraction (θ), is used to measure the relative distance between two loci in 
centiMorgans (cMs): one cM corresponds to a recombination fraction of 0.01 (1%). If θ is equal 
to 0.5, the two loci show no linkage and they are inherited independently. Therefore, if the two 
loci are linked, the θ is smaller than 0.5 (Pulst, 1999). The background frequency of 
recombinations is therefore determined by experiental genetic maps that describe a relative 
distance of loci in cMs; the greater the recombination frequency, the longer the distance between 
the two loci (Pulst, 1999).  
In family-based linkage analysis, polyporhic markers are genotyped from affected and healthy 
members of the family, which are then used to test for co-inheritance with the disease. Based on 
the inheritance model of the disease in the family, the affected family members are expected to 
share alleles, at the disease causing genomic region, either in one chromosome (dominant and X-
linked inheritance) or in both sister chromosomes (recessive inheritance).  
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In parametric linkage analysis, the genetic model for the disease inheritance is specified, and the 
penetrance as well as the allele frequency of the disease allele is defined. Nonparametric linkage 
analysis is a model-free method, in which no assumption of the inheritance model needs to be 
made. Linkage analysis, where multiple markers (more than two) are used to evaluate the linkage 
of the markers with the disease, is called multipoint linkage analysis. This increases the 
informativeness of a series of markers and enables effective detection of the linked chromosomal 
regions. In multipoint linkage analysis, the hypothesis of linkage between the disease gene and a 
set of markers is compared to the hypothesis of no linkage between the disease gene and a set of 
markers (Kruglyak et al., 1996). 
The statistical significance of linkage is estimated by the logarithm of odds (LOD) score (Morton, 
1955). The LOD score is a 10
th
 base logarithm of the likelihood that the two loci are linked 
compared to the likelihood that the loci are not linked. Positive LOD values indicate that linkage 
exists and negative that there is no linkage. By convention, a LOD score over 3 denotes a strong 
likelihood that the genetic variant underlying the trait is located close to the marker. In practice, 
such LOD score is very hard to obtain from a single family, but the test allows summing of the 
LOD scores from different families. 
6.2 High-throughput sequencing 
Since the completion of the first human genome sequence (Lander et al., 2001; Venter et al., 
2001International Human Genome Sequencing Consortium, 2004), major improvements in 
sequencing technologies have been made. Developments especially concerning sample 
preparation and automation as well as parallelization of the sequencing reactions have led to 
significant increase in the speed with concurrent reduction in costs (Mardis, 2008).  
Today, various high-throughput sequencing, also known as next-generation or massive-parallel 
sequencing methods are available. The commonly used sequencing methods include Illumina 
(Illumina), the SOLiD System (Applied Biosystems), 454 Life Sciences (Roche), and Complete 
Genomics (BGI-Shenzhen) (Mardis, 2008; Mardis, 2013). Using slightly different approaches, 
these technologies amplify single strands of DNA from a fragmented DNA library (usually 350-
400bp in length) and sequence the amplified product. The libraries are produced by attaching a 
method specific linker and/or adapter sequences to the ends of the DNA fragments. These linker 
sequences enable the selective amplification of the fragmented DNA library in a massively 
parallelized PCR reaction and also the subsequent sequencing of the amplified products, or 
sequence reads (Mardis, 2008; Mardis, 2013).  
In Illumina sequencing, DNA is first shared to blunt ended fragments and adapter sequences are 
ligated to both ends. These enable the fragments to bind to the surface of a glass chamber called 
flow cell. When the fragments are attached to the flow cell surface, bridge amplification is 
performed to create a cluster of fragments consisting of up to 1000 copies of each fragment. For 
sequencing, Illumina uses sequencing by synthesis technology which uses four reversible 
terminated fluorescently labelled nucleotides. In each sequencing cycle, a single fluorescently 
labelled nucleotide is incorporated to the growing DNA sequence by DNA polymerase. The 
fluorescent signal is emitted and imaged to identify the incorporated nucleotide after which it is 
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enzymatically cleaved to enable addition of the next nucleotide in the growing DNA chain 
(Ulahannan et al., 2013).  
In most of the high-throughput sequencing studies employing human DNA, the sequencing reads 
are mapped against the human reference genome. A commonly used, relatively low memory 
using alignment method is the Burrows-Wheeler transformation (Li and Durbin, 2010), which is 
based on effective sorting and organization of strings of characters. An example of a widely used 
read mapping program is Burrows-Wheeler Alignment (BWA) (Li and Durbin, 2009; Li and 
Durbin, 2010). After read mapping, the nucleotides differing from the reference genome are 
detected using variant calling programs. Multiple statistical programs have been developed and 
commonly used programs include for example Sequence Alignment/Map tools (SAMtools, Li et 
al., 2009), and Genome Analysis Toolkit (GATK, McKenna et al., 2010).  
Due to the massive amount of data that the high-throughput sequencing produces, the processing 
of the data is computationally demanding, and development of more efficient methods for data 
storage and handling is constant. Novel computational tools are also needed for the mapping, 
variant calling and analyzing the data. Especially difficult regions for the current sequencing and 
mapping technologies are repeated sequences, insertions and deletions and larger chromosomal 
alterations (Ulahannan et al., 2013). The above mentioned difficulties can at least to some extend, 
be surpassed by novel single-molecule sequencing methods, such as the GridION™ (Oxford 
Nanopore Technologies) and the PacBio RS II (Pacific Biosciences), that do not necessary 
require amplification of the DNA prior sequencing and can sequence longer reads that are easier 
to uniquely map to the reference human genome. 
7. Tumor susceptibility conditions scrutinized in this study 
7.1 Kaposi sarcoma 
Kaposi sarcoma (KS) is a malignant soft tissue sarcoma first described by Morizt Kaposi in 1872 
as an indolent sarcoma of the skin affecting mainly elderly Ashkenazi Jewish men (Kaposi, 1872). 
KS commonly manifests as a slowly progressing single or multifocal purple lesions on the skin of 
the extremities or oral mucosa. However, the disease course is variable and KS can also manifest 
as an aggressive metastatic disease involving multiple organs. 
Over hundred years later from the initial description of KS, clinicians in the major cities in the 
USA were faced with a sudden outbreak of KS among young homosexual men with acquired 
immunodeficiency syndrome (AIDS) (Friedman-Kien, 1981). Epidemiological evidence 
suggested involvement of an infectious agent underlying KS (Beral et al., 1990; Lifson et al., 
1990), and in 1994 DNA sequences of a novel gamma herpesvirus, called Kaposi sarcoma-
associated herpesvirus (KSHV or later named HHV8), were identified from the KS biopsies of 
AIDS patients (Chang et al., 1994).  
HHV8 is classified as Group 1 carcinogen to humans by IARC (IARC Working group, 2012b; 
Lifson et al., 1990, Tables 1 and 2), and it is present in all KS tumors. The neoplastic cells are 
called ‘spindle cells’, and they are the main repository of HHV8 in the tumor (Boshoff et al., 
1995). In addition to the spindle cells, KS tumors are comprised of large infiltrates of normal cell 
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types including macrophages, lymphocytes, plasma cells and red blood cells (Lifson et al., 1990; 
IARC Working group, 2012b).  
KS can be classified into four distinct epidemiological entities. These are classic KS (cKS) that 
affects mainly elderly men of Mediterranean or Eastern European Jewish origin; endemic KS, 
that involves individulas from Central and Eastern Africa; iatrogenic KS, affecting individuals 
that are on immunosuppressive medication; and epidemic or AIDS-related KS seen in HIV-
infected individuals. The prevalence of KS varies geographically being extremely rare with age 
standardized incidence of less than 1 per 100 000 in males in most of the other continents 
whereas in the central parts of Africa it is the most common cancer with an incidence of over 22 
per 100 000 in males (Parkin et al., 1999; Mesri et al., 2010). In Finland the overall incidence of 
KS is higher among males than in females, with an average incidence of 0.2 in males and 0.1 in 
females, per 100 000 person-years, age-adjusted to the World Standard Population 
(www.syoparekisteri.fi, updated 24.04.2014). In 2011, 14 new KS cases were diagnosed in 
Finland, of which 10 were males and 4 females (www.syoparekisteri.fi, updated 24.04.2014). In 
Nordic countries the incidence of KS has been reported to differ significantly, with Sweden 
having the highest and Denmark the lowest rates (Hjalgrim et al., 1996). 
Although HHV8 can be detected in all KS tumors, the infection alone is not sufficient to induce 
the development of KS. Genetic predisposition to cKS has been studied in a few unrelated 
children with recessive loss of function mutations, two with inherited immunodeficiency caused 
by mutations in IFN-γR1 and WAS  (Camcioglu et al., 2004; Picard et al., 2006) and two 
idiopathic cases with mutations in STIM1 and TNFRSF4 (Byun et al., 2010; Byun et al., 2013). In 
addition, genetic variants in FCGR3A, IL8RB, and IL-13 (Brown et al., 2005; Brown et al., 2006) 
as well as certain HLA-alleles have been associated with cKS predisposition, but these results 
have remained inconclusive. 
7.2 Nodular lymphocyte predominant Hodgkin lymphoma 
Hodgkin lymphoma (HL) is a group of malignant diseases of adaptive immunity. HL originates 
from lymphocytes, more precisely mature B-cells, and accounts for under 10% of all lymphoid 
malignancies (Swerdlow et al., 2008). Hodgkin lymphoma involves two separate disease entities: 
classical HL, and Nodular lymphocyte-predominant HL (NLPHL) (Swerdlow et al., 2008). 
Classical HL can be further subdivided into nodular sclerosing, mixed cellular, lymphocyte-rich 
and lymphocyte-depleted HL, of which most common is the nodular sclerosing type. Classical 
HL is a much more common HL subtype than NLPHL, which accounts only for 3-5% of the 
cases (Colby et al., 1982; Morton et al., 2006; Nogova et al., 2008).  
In Finland, 100-120 new HL cases are diagnosed every year, and the portion of NLPHLs is 
described to be as high as 16% (Saarinen et al., 2013). NLPHL is usually diagnosed as a 
localized early stage disease and most common symptoms include lymphadenopathy of 
peripheral lymph nodes in the neck, groin, arm pit, or cervix (Swerdlow et al., 2008; Lee and 
LaCasce, 2009). Compared to the classical HL, NLPHL has a slightly elevated age at diagnosis 
(30-50 years), unimodal age distribution, high male to female (3:1) predominance, and less 
aggressive clinical course with better prognosis (de Jong et al., 2006; Nogova et al., 2008). 
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Although NLPHL is rarely fatal, and its 10 year overall survival rate is over 80%, relapses 
happen frequently and a transformation to a non-HL, specifically to a diffuse large B-cell 
lymphoma, is sometimes observed (Al-Mansour et al., 2010; Biasoli et al., 2010). 
The lymphocyte-predominant cells are considered to be the tumor cells in NLPHL, and they are 
not found in other HL subtypes. These cells are sometimes also called ‘popcorn cells’ because of 
the large folded or multilobed nuclear morphology (Mason et al., 1994). Lymphocyte 
predominant cells constitute only about 1% of the cells in the tumor, the rest being infiltrating 
normal polyclonal inflammatory cells, such as follicular dendritic cells and macrophages, 
organized in a germinal-center like formation (Swerdlow et al., 2008; Kuppers, 2009).  
Histopathologically NLPHL may resemble other lymphomas, especially T-cell rich B-cell 
lymphoma and lymphocyte-rich classical HL, and thus immunohistochemistry is often used to 
facilitate the diagnosis (Swerdlow et al., 2008; Smith, 2010). Commonly used 
immunohistochemical stainings include CD20, CD45 and CD79, CD30, CD15, and CD3 (Smith, 
2010). Lymphocyte predominant cells are generally CD20, CD45, and CD79-alpha positive, but 
in contrast to the tumor cells in classical HL, they are commonly CD30 and CD15 negative. CD3 
stains the normal T-cells that usually surround the lymphocyte predominant cells (Swerdlow et 
al., 2008).  
The etiology of NLPHL is poorly understood. Due to the rarity of NLPHL, the epidemiological 
studies usually discuss HL as one entity. In contrast to certain other subtypes of HL, previous 
infection with EBV is considered not to be relevant in NLPHL (Anagnostopoulos et al., 2000). 
An increased risk of NLPHL has been reported in the first-degree relatives of NLPHL patients, 
suggesting shared genetic or environmental factors (Saarinen et al., 2013). A few patients with 
autoimmune related lymphoproliferative syndrome, caused by germline mutation in FAS, have 
also been reported to have developed NLPHL (Sneller et al., 1997; van den Berg et al., 2002). 
7.3 Meningioma 
Meningiomas are the most common primary tumors of the central nervous system with incidence 
of approximately 4 and 9 per 100 000 person-years in the United States, in males and in females, 
respectively (CBTRUS Statistical Report, 2012). Meningiomas occur most commonly in 
individuals over 50 years of age, with a peak in the sixth and seventh decades of life (Louis et al., 
2007). In Finland, the World Standard Population age-adjusted incidence of meningiomas, is 1.6 
in males and 5.5 in females, per 100 000 individuals (Larjavaara et al., 2008). In Finland, as well 
as in many other industrialized countries however, the incidence of meningiomas has been rising 
during the past few decades (Klaeboe et al., 2005; Larjavaara et al., 2008).   
Meningiomas originate from the meninges, which are the membranes surrounding the central 
nervous system, and arachnoidal cap cells are thought to be the origin of the tumorous cells. 
Great majority of meningiomas (90%) are found intracranially; the rest are located around the 
spinal cord. Multiple lesions are observed in 4-10% of the patients (Nahser et al., 1981; Locatelli 
et al., 1987; Antinheimo et al., 2000; Huang et al., 2005).  
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The biological spectrum of meningiomas is wide, and meningiomas are dividied into a number of 
different histological subtypes. The most common are meningothelial, fibrous, and transitional 
subtypes, and these are usually benign and slowly growing (grade I) tumors. Atypical (grade II) 
and anaplastic (grade III) features are seen in less than 10% of all meningiomas (Louis et al., 
2007). Although meningiomas seldom metastasize, they can cause serious neurological 
symptoms by pressing adjacent structures. However, they can also be asymptomatic and go 
entirely unnoticed and up to 3% of meningiomas are found only at autopsy (Krampla et al., 2004; 
Vernooij et al., 2007).  
The main treatment option for meningiomas is surgical removal, but the recurrence rate is high 
and up to 20% of the grade I tumors recur after successful resection (van Alkemade et al., 2012). 
The grade II and III meningiomas are generally more aggressive, and they are associated with 
shorter survival times and higher recurrence rates of 29-52% and 50-94%, respectively (CBTRUS, 
2012). 
Risk factors for meningioma include ionizing radiation, and certain hereditary tumor suppressor 
syndromes are associated with increased risk of meningioma, including Neurofibromatosis type 2 
(MIM #101000), Cowden syndrome (MIM #601728), and Werner syndrome (MIM #277700), 
caused by mutations in NF2, PTEN, and RECQL2, respectively (Flint-Richter and Sadetzki, 2007; 
Gorlin, 1987; Lauper et al., 2013; Lloyd and Evans, 2013; Robinson and Cohen, 2000). In 
addition to these, a couple of families with meningiomas and a germline SMARCB1 mutation, 
usually predisposing to familial schwannomatosis and rhabdoid tumors (MIM #162091 and 
609322), have been described (Bacci et al., 2010; Christiaans et al., 2011; Melean et al., 2012; 
van den Munckhof et al., 2012). More recently, inherited loss-of-function mutations in 
SMARCE1 were identified to predispose to familial clear cell meningiomas (Smith et al., 2013; 
(Smith et al., 2014)). 
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AIMS OF THE STUDY 
 
This study was conducted to identify novel familial cases with unknown tumor predisposing 
conditions and to study genetic predisposition in them.  
 
The more specific aims were: 
 
1. To assess familial aggregation of different tumor types in Finland and to identify novel 
tumor predisposition families through systematic search in the Finnish Cancer Registry 
database 
 
2. To identify susceptibility genes and elucidate their functions in families with Kaposi 
sarcoma, nodular lymphocyte predominant Hodgkin lymphoma and multiple intracranial 
meningioma   
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MATERIALS AND METHODS 
Detailed information of the study subjects, samples and methods are described in the original 
articles (I-IV). Manufacturer’s instructions and protocols have been followed if not otherwise 
indicated. 
1. Ethical considerations 
The studies were approved by the Ministry of Social Affairs and Health in Finland and by the 
local ethics review committee of the Hospital District of Helsinki and Uusimaa (HUS). Informed 
consent was obtained from the patients from whom fresh sample materials were collected. The 
use of archival formaline-fixed paraffine-embedded (FFPE) samples was authorized by the 
National Supervisory Authority for Welfare and Health (Valvira).  
2. Study subjects and samples 
2.1 Patients in the Finnish Cancer Registry (I) 
In study I, all neoplasms registered in the Finnish Cancer Registry (FCR) in 1953-2011 were 
initially considered. This included 962 355 cancerous and 212 685 non-cancerous lesions, 
classified based on the International Classification of Diseases for Oncology 3
rd
 edition (ICD-O-3) 
(World Health Organization, 2000). The non-cancerous lesions registered in FCR include basal 
cell carcinoma of skin, polycythemia vera, carcinoma in situ of breast, carcinoma in situ of 
bladder, non-invasive neoplasm of cervix uteri, borderline tumor of ovary, and papillary 
urothelial neoplasm of low malignant potential. 
For the purpose of the clustering, the tumors were classified into 55 topography and 94 
morphology groups, respecting the pathological similarities of different morphologies and 
topographies in the ICD-O-3 (Tables S1 and S2 in the online supplementary, study I). All 
possible topography-morphology combinations were considered, and combinations with at least 
two patients in FCR were used to define a tumor type in the clustering. Altogether 878 493 
patients were linked to the National Population Registry (NPR) using indentity numbers to obtain 
information on their family names at birth and birth municipalities.  
2.2 Kaposi sarcoma patients (II) 
Figure 1 summarizes the samples available from the Finnish KS family (study II). Additional 
samples used in study II included: nine Finnish familial KS cases, that belonged seven KS 
families (with two affected individuals) identified in study I, 56 sporadic Finnish KS patients, 
DNAs of previously reported Israeli cKS family from Israel (Guttman-Yassky et al., 2004), and 
26 familial cKS cases from Italy.  
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Figure 1. The Finnish Kaposi sarcoma (KS) family with five affected individuals in two generations. 
Round symbols denote females and square symbols males. Proband is indicated with an arrow and line 
through indicates a deceased individual. Numbers under the symbols denote the age at the KS diagnoses 
and letters the sample materials available (D: genomic DNA, T: DNA from formalin fixed paraffin 
embedded tumor tissue, R: total RNA from peripheral blood, P: peripheral blood mononuclear cells, L: 
EBV-transformed lymphoblast cell line). The pedigree has been slightly modified for confidentiality. 
2.3 Hodgkin lymphoma patients (III) 
Peripheral blood samples from 11 family members of the previously described Finnish NLPHL 
family (Saarinen et al., 2011) were collected and used for extracting genomic DNA and 
constructing EBV-transformed lymphoblastoid cell lines (Figure 2). Additional peripheral blood 
samples were also collected from ten family members (Figure 2) for RNA extraction and 
transcriptome analysis. FFPE tumor samples from the four affected family members were also 
collected and these were used for confirming the lymphoma diagnoses as well as for EBV-testing 
(Figure 2).  
Additional samples used in the NPAT screening included germline DNA samples from three 
previously published NLPHL families from UK (Indian; two affected siblings, Campbell et al., 
2004), France (Basque; father and two sons, Bauduer et al., 2005) and Turkey (mother and child, 
Unal et al., 2005), 73 FFPE tumor tissue DNA from Finnish HL patients, germline DNA samples 
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from 93 HL cases from UK, and NLPHL-derived DEV cell line (Atayar et al., 2006). The 73 
Finnish HL cases included 27 familial cases (with at least 2 HL cases, 2 NLPHL cases, or one HL 
and one NLPHL case in the family), 38 early onset NLPHL cases (less than 30 years at the time 
of diagnosis), and 8 NLPHL cases from the same geographical region as the NLPHL-Family 1. 
The HL cases from UK included 26 patients with at least one relative affected by a 
lymphoproliferative disorder and 67 sporadic HL cases. 
 
 
Figure 2. The Finnish nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) family with four 
affected cousins. Round symbols denote females and square symbols males. The ages at cancer diagnoses 
are marked underneath the symbols. The index case is marked with an arrow and deceased individuals are 
marked with a line through. The letters under the symbols denote the sample materials available (D: 
germline DNA, T: DNA from formalin fixed paraffin embedded tumor tissue, R: total RNA from 
peripheral blood, L: EBV-transformed lymphoblast cell line). The pedigree has been slightly modified for 
confidentiality. 
2.4 Meningioma patients (IV) 
The family of five meningioma patients was initially identified by a clinician Pia Alhopuro. The 
samples and sample types available from the Finnish meningioma family members are marked in 
Figure 3. Additional samples used in SUFU screening consisted of germline DNA samples of 77 
meningioma patients that had participated in the Interphone study (INTERPHONE Study Group, 
2010), 35 NF2 mutation negative multiple meningioma patients from UK, 5 familial meningioma 
patients (≥2 first-degree relatives with meningioma) from UK, and 4 Finnish NF2 mutation 
negative patients with multiple meningiomas. In addition, 41 Finnish FFPE meningioma samples, 
of which 6 were from familial Finnish meningioma patients (≥2 first-degree relatives with 
meningioma), 20 from putative familial meningioma cases (identified in the clustering effort in 
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study I), 6 from meningioma patients from the same geographical region with the Finnish 
meningioma family, and 9 from patients with early onset meningioma (≤35 years), were also 
used for SUFU screening. 
 
Figure 3. Pedigree of the Finnish meningioma family with five affected individuals. Round symbols 
denote females and square symbols males. The proband is indicated with an arrow and line through 
indicates a deceased individual. Numbers under the symbols denote the age at diagnoses and letters the 
sample materials available (D: genomic DNA, T: DNA from formalin fixed paraffin embedded tumor 
tissue: R, total RNA from peripheral blood, L: EBV-transformed lymphoblast cell line). The pedigree has 
been slightly modified for confidentiality. 
2.5 Control samples (II, III, and IV) 
Varying numbers of DNA samples extracted from peripheral blood of eligible Finnish blood 
donors were used as population specific controls in the studies II, III, and IV. The blood samples 
were acquired from the Finnish Red Cross Blood Transfusion Service. In study III, additional 
samples from healthy control individuals (n=177) from UK, participating in the National Study of 
Colorectal Cancer Genetics (Penegar et al., 2007), were also used.  
To filter the common polymorphisms from the high-throughput sequencing data, we used 149 
Finnish genomes (in study II) and 13 and 78 Finnish exomes (in studies III and IV, respectively) 
sequenced for purposes of other projects in our laboratory. In study II, Finnish cohort of 1000 
genomes (n=93, http://browser.1000genomes.org/), was used for additional controlling. In studies 
III and IV, additional controlling was performed using variants reposited in the dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/).  
2.6 DNA and RNA extractions (II, III and IV) and cDNA synthesis (II and III) 
The genomic DNA samples were extracted from peripheral blood and lymphoblastoid cell lines 
using the non-enzymatic DNA extraction method (Lahiri and Nurnberger, 1991) or DNeasy 
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Blood & Tissue kit (Qiagen). The genomic DNA from FFPE tissue sections was extracted either 
by standard phenol-chloroform protocol with proteinase K treatment or by Nucleo Spin FFPE 
DNA kit (Macherey-Nagel).The total RNA was extracted from peripheral blood using PAXgene 
Blood RNA kit (Qiagen) or from lymphoblastoid cell lines with RNeasy kit (Qiagen) or PureLink 
RNA Mini kit (Life Technologies).  
Random primers (Promega), Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
buffer (Promega), Deoxynucleotides (dNTPs; Bioline or Finnzymes), RNAase inhibitor 
(Promega), M-MLV enzyme (Promega), and 200-1000ng of total RNA was used in the cDNA 
synthesis. The random primers were annealed at 65ºC (5min) and the reverse transcription was 
performed by incubating the reactions at 42ºC for 50min followed by incubation at 95 ºC for 
10min.   
3. Clustering of the patients in the Finnish Cancer Registry (I) 
3.1 Clustering procedure (I) 
In study I, two clustering efforts were performed. One was based on tumor type, municipality of 
birth, and family name at birth (MN-clusters) of the patients and the other on tumor type and 
family name at birth only (N-clusters). The observed (O) number of the patients for the different 
tumor types in FCR was calculated in a stratum specified by municipality, family name at birth, 
sex, and year of birth. Proportion of persons, in each characterized strata reflecting the entire 
Finnish population, was obtained from NPR. When these proportions were multiplied with the 
total sex and birth-year defined number of cancer cases in FCR, the expected (E) number of 
patients was defined. The stratum-specific O and E values were added up over the gender and 
birth year categories and for each cluster O/E ratios were calculated with 95% confidence 
intervals, assuming a Poisson distribution of observed numbers.  
3.2 Cluster score calculation (I) 
To calculate the cluster score, we selected MN-clusters with lower limit confidence interval (CI-
low) ≥10. The number of individuals in these was divided by the total number of patients with the 
same tumor type per 100 000 persons in Finland. To estimate if the obtained cluster score was 
different than the expected ratio two-sided Poisson test was calculated with 95% confidence 
interval. The p-values were adjusted for multiple testing with false discovery rate (Benjamini and 
Hochberg, 1995). 
4. Genetic analyses 
4.1 Genotyping (II, III and IV) 
Genome-wide SNP genotyping was performed on Affymetrix 50K Xba SNP array (Affymetrix) 
(study III), Human610-Quad DNA analysis BeadChips (Illumina) (studies II and IV), or 
HumanOmniExpress-FFPE Bead Chip (Illumina) (study II). The sample preparation, 
hybridization, and scanning was performed at the Institute for Molecular Medicine Finland 
(FIMM) Genome and Technology Center. BeadStudio or GenomeStudio (Illumina) was used to 
call the genotypes and check the genotype qualities.  
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In study III, finemapping of the the linked regions was performed by genotyping microsatellite 
markers that were identified using Tandem repeat finder (Benson, 1999) or the Ensembl database 
(www.ensembl.org). The markers are listed in the online supplement (Table S1) of the original 
article (study III). The PCR products were run on ABI3730 capillary electrophoresis device 
(Applied Biosystems) at FIMM Technology Center, and the results were scored using 
GeneMarker software (SoftGenetics).  
4.2 Transcriptome analysis (III and IV) 
For the transcriptome analyses, the total RNAs were hybridized on a GeneChip Human Genome 
U133 Plus 2 (study III) or GeneChip Human Exon 1.0 ST Array (study IV) (Affymetrix). The 
sample preparations, hybridizations, and chip scannings were done at Biomedicum Functional 
Genomics Unit (FuGU) (Helsinki, Finland). Prior to normalization, the probes were annotated 
using Brainarray custom CDF file (ENTREZG, version 11.0.1) (Dai et al., 2005). The data was 
normalized using robust multichip average normalization in R, using affy package. Fold change 
and two-tailed t-test with the equal variance assumption were calculated to evaluate NPAT and 
NF2 expression differences in studies III and IV, respectively.  
4.3 DNA copy number analysis (IV) 
Human genome Comparative Genomic Hybridization (CGH) Microarray 105A (Agilent) was 
used to study the genome wide copy number variation (study IV). The genomic DNA from three 
affected female patients (II-2, II-5 and II-12; Figure 3) were pooled and hybridized on one array, 
and the genomic DNA from the affected male patient (II-13; Figure 3) was hybridized separately 
on another array. The sample preparation, hybridization, and scanning was done at FuGU. Data 
was analyzed and the CNVs called using circular binary segmentation algorithm to segment log 
R ratios into regions of estimated equal copy number (Olshen et al., 2004).  
4.4 Linkage analysis (II, III, and IV) 
Multipoint linkage analyses were performed using Merlin (Abecasis et al., 2002). In studies II 
and IV, Merlin’s error detection algorithm was used to mark unlikely genotypes and pedwipe 
command to remove the problematic genotypes. In study IV, X chromosomal genotypes were 
analyzed separately with X chromosome specific version of Merlin (MINX). 
In study II, genotypes were produced from the affected cousins (III-5 and III-6; Figure 1). SNPs 
shared between the two different platforms with minor allele frequency (MAF) ≥ 0.1 were 
selected for the linkage analysis. MAFs were determined using the CEPH population (Utahns 
originated from northern and western Europeans) in the HapMap phaseII data set (International 
HapMap Consortium et al., 2007). A parametric linkage analysis with dominant inheritance 
model was performed, and consecutive markers with a positive LOD score and within 1cM 
distance from each other were considered.  
In study III, both recessive and dominant parametric linkage analysis with ‘affected only’ 
strategy, with 100% penetrance, 0% likelihood of phenocopies, and in which healthy family 
members were coded as unknown for the disease status, was performed. Haplotypes were 
constructed using Merlin ‘best’ function.  
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In study IV, non-parametric linkage analysis was used. Individuals with multiple meningiomas 
(II-2, II-5, and II-13; Figure 3) were coded as affected, siblings without meningomas as 
unaffected (II-7 and II-11; Figure 3), and the sibling with a single meningioma (II-12; Figure 3), 
and the three children of the affected family members (children of II-2, II-5, and II-7; Figure 3) as 
unknown. Allele frequencies were generated from the genotypes of the family and from 265 
healthy Finnish control individuals provided by the Nordic Center of Excellence in Disease 
Genetics consortium.  
4.5 Exome and genome sequencing (II, III, and IV) 
The details of the exome capture kits, exome and genome sequence analysis tools, and analysis 
criteria are summarized in Table 3. In study II, the germline genome of III-5 (Figure 1) was 
sequenced from peripheral blood derived DNA using Illumina’s paired-end sequencing chemistry. 
Two size-selected libraries (~1000bp and ~500bp) were sequenced using Illumina HighSeq2000 
at FIMM Technology Center. The genomic library preparation and sequencing of the FFPE 
tumor sample of III-6 (Figure 1), was performed as an Illumina service (Illumina Cambridge Ltd, 
Little Chesterford, Essex, UK). Paired-end sequencing was used in all high-throughput 
sequencing applications and the sequencing was performed using Illumina sequencing chemistry 
and mahcines either at Karolinska Institutet (Sweden) or FIMM Technology Center. 
In study II, the exomes and genomes were processed with an in-house pipeline (Saarinen et al., 
2013) with additional recalibration step. The adapter sequences were trimmed from the sequence 
reads using a script, and the read aligment was performed using the Burrows-Wheeler Aligner 
(BWA, Li and Durbin, 2010). Duplicate reads were removed with Markduplicates 
(http://picard.sourceforge.net), and the read processing and variant calling was performed 
following the Genome Analysis Toolkit (GATK, McKenna et al., 2010) best practices 
(http://www.broadinstitute.org/gatk/guide/best-practices). Variant qualities and filtering were 
performed using an in-house high-throughput sequencing data visualization and analysis tool, 
“RikuRator”. The variant annotations were based on Ensembl 71 (released in April 2013). 
To identify structural genomic variants (SVs) in study II, BreakDancerMax (v1.2) (Chen et al., 
2009) was used. To call a SV, a minimum of 2 discordant read pairs (-r 2) and alternative 
mapping quality of 35 (-q 35) were required. The called breakpoints were flanked with 1000bp 
region up- and downstream for further filtering. SVs present in 22 Illumina (detected with with 
BreakDancerMax) and 27 Complete Genomics (Complete Genomics Inc., Mountain View, CA, 
USA) in-house control genomes were filtered from the data. The breakpoints that colocalized 
with Segmental Dups (UCSC track table, Bailey et al., 2001) or Hi Seq Depth regions (UCSC 
track table, Pickrell et al., 2011) were also filtered out.  
In studies III and IV, the exome sequencing data analysis was performed using commercial 
NextGENe software (Softgenetics) with NCBI36/hg18 and GRCh37/hg19 as the reference 
genome, respectively.  
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Table 3. The high-throughput sequencing methods and analysis tools used in studies II, III and IV 
 Study II Study III Study IV 
Exomes Genomes 
Samples III-5 and III-2; 
Figure 1 
7 Finnish 
familial KS 
cases 
III-5 and III-6
***
; 
Figure 1 
III-1; Figure 
2 
II-2, II-5 and 
II-13; Figure 3 
Exome kit Agilent 
SureSelect 
Human All exon 
Kit v1.0 
Agilent 
SureSelect 
Human All 
exon Kit v1.0 
or XT 
HumanAllExon 
- Agilent 
SureSelect 
Human All 
exon Kit v1.0 
Agilent 
SureSelect 
Human All 
exon Kit v1.0 
Sequencing 
machine 
Illumina Genome 
Analyzer II and 
HighSeq 2000 
Illumina 
HighSeq 2000 
Illumina 
HighSeq 2000 
Illumina 
Genome 
Analyzer II 
Illumina 
Genome 
Analyzer II 
Read length  58bp or 82bp 82bp 100bp 82bp 58bp , 77bp or 
82bp 
Analysis 
tools 
In-house 
alignment and 
variant calling 
pipeline, 
visualization and 
analysis tool 
RikuRator 
(unpublished)
 
In-house 
alignment and 
variant calling 
pipeline, 
visualization 
and analysis 
tool RikuRator 
(unpublished) 
In-house 
alignment and 
variant calling 
pipeline, 
visualization and 
analysis tool 
RikuRator 
(unpublished) or 
Illumina 
pipeline
***
 
NextGENe 
v1.94 
(Softgenetics) 
NextGENe 
v2.1 
(Softgenetics) 
Reference 
genome 
GRCh37/hg19 GRCh37/hg19 GRCh37/hg19 NCBI36/hg18 GRCh37/hg19 
Minimum 
read 
coverage  
5 5 5 5 4 
Percentage 
of variant 
allele 
25 % 25 % 25 % 20 % 20 % 
Controls 149 genomes and 
1000 Genomes 
Finnish genomes 
(MAF≥ 0.005) 
149 genomes 
and 1000 
Genomes 
Finnish 
genomes 
(MAF≥ 0.005) 
149 genomes and 
1000 Genomes 
Finnish genomes 
(MAF≥ 0.005) 
13 exomes 
and dbSNP 
variants 
78 exomes and 
dbSNP 
variants 
Analyzed 
regions 
linked regions, 
exons and exon-
intron junctions
*
 
exons and 
exon-intron 
junctions
*
 of 
STAT4 
associated 
genes
**
 
linked regions, 
exons and exon-
intron junctions
*
 
linked 
regions, 
exons and 
exon-intron 
junctions
*
 
linked regions, 
exons and 
exon-intron 
junctions
*
 
*
two bps to intron from the exon start and end sites;
**
STAT4 interacting, regulating or regulated genes 
identified through the use of QIAGEN’s Ingenuity Pathway Analysis (Supplementary Table 2, study II, 
and IPA®, QIAGEN Redwood City, www.qiagen.com/ingenyuity);
***
the FFPE tumor sample of III-6 
sequenced and processed at Illumina Cambridge Ltd, Little Chesterford, Essex, UK.  
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4.6 PCR and Sanger sequencing (II, III, and IV) 
Primers for PCR were designed using Primer3 (Koressaar and Remm, 2007; 
http://bioinfo.ut.ee/primer3-0.4.0/primer3/) or ExonPrimer programs 
(http://ihg.gsf.de/ihg/ExonPrimer.html). PCRs were performed in 25µl volume using AmpliTag 
Gold (Applied Biosystems), Phusion
® 
High-Fidelity (Finnzymes), or Expand long template PCR 
system’s (Clonetech) DNA polymerases. The PCR products were run on agarose gel and purified 
with ExoSAP-IT (USB Corporation) or illustra™ ExoSTAR 1 enzymes (VWR International). 
The purified products were sequenced at FIMM Technology Center. Sequences were analyzed 
manually with Chromas (http://technelysium.com.au) and using Mutation Surveyor software 
(Softgenetics). 
4.7 Loss of heterozygosity analysis (IV) 
Loss of heterozygosity (LOH) was studied by PCR, followed by Sanger sequencing, and scored 
manually by comparing the allele peak intensities of the germline and tumor tissue samples. For 
each variant site at least three parallel PCRs were performed and sequenced separately. LOH was 
scored if majority of the sequences (2/3) showed reduced wild type allele intensity.   
5. Protein analyses 
5.1 Serological testing of human herpes virus 8 (I and II) 
In study I, serological testing was performed in age and sex matched serum samples of 200 
Eastern and 200 Western Finns obtained from the National Public Health Institute’s Health 2000 
cohort. In study II, the serological testing was performed from the plasma of the additionally 
collected c.1337C>T STAT4 variant carriers and their age and sex matched wild-type controls 
(Figure 1). The serological analyses were done at HUSLAB (Helsinki, Finland) with direct 
HHV8 IgG antibody Enzyme Linked ImmunoSorbent Assay. 
5.2 In silico predictions and modelling (II, III and IV) 
PolyPhen2 (Adzhubei et al., 2010) and/or SIFT (Kumar et al., 2009) were used to predict the 
effects of amino acid substitutions in studies II, III, and IV. In studies II and IV, the three 
dimensional protein models were produced with Crystallographic Object-Oriented Toolkit 
(COOT, Emsley and Cowtan, 2004), and the figures were made with PyMOL (DeLAno, 2002). 
In study II, structural alignments of STAT1 and STAT3 (Protein Data Bank entries 1BG5 and 
1BG1) were used to produce the model, since no crystal structure exist on STAT4. The 
p.Thr446Ile mutation was modelled using the to the structure of STAT3 (1BG1). In study IV, the 
crystal structure of the human N-terminal domain of SUFU was used (Protein Data Bank entry 
1M1L). 
5.3 Flow cytometry (II) 
Ficoll-Paque solution (GE Healthcare) was used to separate peripheral blood mononuclear cells 
(PBMCs), and the CD4+ T cells were isolated using CD4+ T cell Isolation Kit II (Miltenyi 
Biotec). For assessment of activated STAT4, the CD4+ T cells were washed and suspended in X-
VIVO-15 culture medium (Lonza) with 2 mM of additional L-glutamin. To induce IL-12R 
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expression, cells were plated on 96-well U-bottom plates (Nunc) for 20 h with anti-CD3/CD28 
beads (Dynabeads® Human T-Expander CD3/CD28, Invitrogen) at bead to cell ratio of 1:1. 
Alternatively, cells were left untreated and then stimulated with IFN-. To activate STAT4, cells 
were stimulated for 30 min at 37C with IL-12p70 (R&D Systems) at a final concentration of 20 
ng/ml or 100 ng/ml, or IFN- (PBL Interferon Source) at a final concentration of 1000 IU/ml and 
fixed for 20 min on ice in 1.75% (w/v) of paraformaldehyde (PFA). Next, ice-cold methanol was 
added to achieve a final methanol concentration of 90%. The suspension was incubated for 10 
min on ice after which the cells were washed with washing-blocking buffer with 10% fetal calf 
serum (FCS) and 0.02% (w/v) sodium azide in phosphate-buffered saline (PBS) and suspended in 
buffer with PE-conjugated STAT4 (pY693) monoclonal antibody (clone 38/p-Stat4; BD 
Biosciences), or an isotype control diluted in washing-blocking buffer, and the suspension was 
incubated for 30 min at room temperature. A pre-mixed cocktail of anti-CD4 FITC (SK3) and 
anti-CD45RO APC (UCHL1) antibodies (BD Biosciences) was added simultaneously to allow 
the identification of naive and memory T-helper cells. Cells were then washed twice with 
washing buffer consisting of 5% FCS and 0.02% sodium azide in PBS, suspended in 1% PFA in 
PBS, and stored overnight at 4C prior to analysis with FACSCalibur flow cytometer (BD 
Biosciences). FlowJo software (Tree Star, Inc.) was used for the analysis of flow cytometry data. 
For intracellular cytokine measurements in T cells, Ficoll-isolated PBMCs were cultured in X-
VIVO-15 culture medium with 2 mM of L-glutamin on 96-well U-bottom plates overnight, and 
10 ng/ml of PMA with 1 µg/ml of ionomycin was added to stimulate intracellular cytokines. 
After 1 h of incubation, 10 µg/ml of brefeldin A was added and the cells were incubated for 
another 4 h. Cells were then harvested and washed with washing buffer. Anti-CD3 FITC (SK7, 
BD Biosciences), anti-CD8 PerCP (SK1, BD Biosciences), and for some tubes also anti-
CD45RO APC antibodies were incubated for 20 min at room temperature, and the cells were 
washed twice with washing buffer. The cells were fixed and permeabilized using Fix/Perm and 
Perm/Wash solutions (BD Biosciences). Anti-IFN-γ PE (25723.11, BD Biosciences) anti-IL-4 
APC (8D4-8, BD Biosciences), anti-IL-17A Alexa Fluor® 647 (eBio64DEC17, San Diego, CA, 
USA), or isotype control antibodies were used for cytokine detection. After washing with 
Perm/Wash buffer, cells were suspended in 1% PFA in PBS and stored overnight at +4ºC, prior 
to FACSCalibur flowcytometer analysis. Prism 6 software was used was used for statistical 
analyses (GraphPad Software Inc.), and Mann-Whitney U test was used to compare the two 
groups.  
5.4 Cloning and site-directed mutagenesis (IV) 
The c.367C>T substitution was generated to a human SUFU cDNA cloned in pCMV5_Myc 
vector (Clonetech) using the QuikChange
®
 Site-Directed mutagenesis kit (Agilent). The primer 
sequences used in the site-directed mutagenesis were: 
5’GTTTTGGTGGTTTTGGCTTTGAGTTGACCTTTTGTCTGAAGAG3’ and 
5’CTCTTCAGACAAAAGGTCAACTCAAAGCCAAAACCACCAAAAC3’. The mutated 
clones were transfected to XL1-blue (Agilent), or TOP10 (Life Technologies) E.coli competent 
cells. The mutant and the wild-type clones were Sanger sequenced to ensure that the constructs 
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did not harbor additional mutations. Plasmid DNA was extracted using QuickLyse Miniprep kit 
(Qiagen) or NucleoBond
®
 Xtra Mini kit (Machrey-Nagel).   
5.5 Cell culturing and production of ShhN conditioned media (IV) 
Human rhabdomyosarcoma cell line (CRL-2061), 293ShhN cell line, and Sufu (-/-) mouse 
embryonic fibroblasts (MEFs) were cultured in Dulbecco’s modified eagle medium (DMEM) 
with 10% FCS and antibiotics. For generation of ShhN conditioned medium, 293ShhN cells were 
changed to low serum medium and the medium collected after 3 days; the medium was cleared 
by centrifugation and stored at +4°C. 
5.6 Luciferase assay (IV) 
Transfections were performed in 12-well plates with FuGENE HD (Roche) using 500 ng of 
pCMV5_Myc vector, (Clonetech) with human wild type or c.367C>T mutant SUFU, 475 ng of 
the luciferase reporter plasmid “SASAKI COOPER” (Taipale et al., 2000), and 25 ng of the 
Renilla luciferase phRL-TK reporter plasmid (Promega) to monitor the transfection efficiency. 
One day (CRL-2061) or two days (Sufu -/- MEFs) after the transfections, the cells were changed 
to low serum (0.5% FBS) medium with or without ShhN medium (1:5 v/v). Subsequently, the 
cells were incubated for 2–3 days after which the luciferase expression was analyzed using Dual-
Reporter Luciferase system (Promega) with Digene DCR-1 luminometer (Diagnostics). The 
assays were conducted in duplicate and repeated at least three times. To calculate relative 
luciferase activity, the firefly luciferase counts were divided by the Renilla luciferase counts. 
5.7 Immunoprecipitation and western blot (IV) 
CRL-2061 cell lysates were centrifuged with a microcentrifuge at full speed at 4°C for 30 min, 
and the supernatant was removed and incubated with anti-Gli1 (H-300) agarose (Santa Cruz) for 
2h at 4°C, followed by washing three times with lysis buffer without protease inhibitors prior to 
addition of a SDS sample buffer. Protein samples were resolved on SDS-PAGE gels and 
transferred to polyvinylidene difluoride membranes. The following antibodies were used in 
detection: goat anti-Myc HRP (ab1261; Abcam) and rabbit anti-Gli1 (ab92611; Abcam), in 
1:5000 and 1:1000 dilutions, respectively. Goat anti-rabbit HRP (1:2000) was used as a 
secondary antibody. The proteins were quantified by Single Dimensional Electrophoretic Gel 
Analysis program from the ImageJ software (v1.46g). 
5.8 Immunocytochemistry (IV) 
Human fibronecting coated glass coverslips (BD) were placed on 6-well plates, and an 
appropriate number of Sufu (-/-) MEFs or CRL-2061 cells were seeded on top one day before 
transfection. The transfection was done with 1 μg of Myc-tagged human wild-type SUFU or 
c.367C>T mutant SUFU expression plasmids using FuGENE HD (Roche). After two days, the 
media was changed to a low serum medium with or without ShhN conditioned medium (1:5 v/v), 
and the cells were incubated for another two days. Specific anti-Myc (Santa Cruz) and Alexa 
594-conjugated anti-mouse (Molecular Probes) antibodies were used for staining. Vectashield H-
1200 (Vector) was used for mounting. Images were recorded with a Zeiss Axioplan 
epifluorescence microscope system and images were labeled using Adobe Photoshop software. 
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RESULTS 
1. Cancer registry based familial clustering of cancers in Finland 
To explore familial accumulation of different tumor types in Finland, we performed a systematic 
clustering of 878 593 patients registered in FCR. Patients were clustered based on tumor type, 
municipality of birth, and family name at birth (MN-clustering), or tumor type and family name 
only (N-clustering). As a result, 25 910 MN-clusters and 12 695 N-clusters, representing 183 
different tumor types and with at least two cancer patients in each cluster, were formed. All 
clusters fulfilled the basic criterion that the number of patients in the cluster (O) was higher than 
the expected (E), based on the distribution of family names and/or birth municipalities in Finland 
and with the lower confidence interval (CI low) greater than or equal to one. The largest number 
of clusters was produced by patients with basal cell carcinoma of the skin, which is the most 
common tumor type in FCR. These clusters represented about 15% and 8% of all MN- and N-
clusters, respectively. 
To estimate the tumor types that showed greater familiality than others, we calculated a cluster 
score, which reflects the fraction of patients belonging to the most significant MN-clusters (CI-
low≥10) compared to the number of patients with the same tumor type in FCR, proportioned to 
100 000 persons in Finland. Many of the tumor types that produced high cluster scores 
represented rare tumor types often related to certain hereditary cancer syndromes, such as 
hemangioblastoma, medullary thyroid carcinoma, hepatic neuroendocrine tumors, and 
nephroblastomas, but included also tumor types with less well characterized genetic etiology 
such as Kaposi sarcoma (KS), small intestine neuroendocrine tumors, myelosclerosis, and 
squamous cancer of the outer female genitals (Table 4). Of the more common tumor types, with 
over 7000 registered patients in FCR, the highest cluster scores were observed for papillary 
thyroid adenocarcinoma (cluster score 0.56), chronic lymphatic leukemia (cluster score 0.48), and 
squamous cell carcinoma of the lip (cluster score 0.35) (Table 1 of the original article, study I). 
1.1 Frequent familial clustering of Kaposi sarcoma in Finland 
To evaluate the efficiency of the method to identify true relatives, we chose to study Kaposi 
sarcoma (KS) with thorough genealogy. KS scored the third highest in our cluster score 
assessment (cluster score 1.91). The genealogy work revealed that 70% of the MN-clustered KS 
cases were true relatives (Figure 4A and 4B), and we identified altogether eight KS families. 
Seven of the identified families had two affected siblings, but one had five affected individuals in 
two generations (Figure 1). In this family, two of the affected family members were identified 
from MN-cluster, one was identified from an additional N-cluster, and one was connected 
through genealogy work.  
We also studied the geographical distribution of the KS-derived MN- and N-clusters in Finland 
and noticed that the clustered KS cases accumulated mainly to the rural areas of western Finland 
(Figure 4A and 4B). Next, we studied the overall distribution of all KS cases in Finland, and that 
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Table 4. The tumor types showing the strongest familial accumulation 
Topography Morphology Cluster 
score 
p-value
* 
No. of 
patien
ts in 
FCR 
No. of  
clusters
** 
 
No. of   
patients 
in 
clusters
**
 
Known 
genetic 
etiology 
central nervous 
system 
hemangioblasto
ma 
4.98 2.77E-14 141 5 13 
 
VHL 
thyroid gland medullary 
carcinoma 
3.55 7.86E-21 335 9 22 
 
 
RET 
skin Kaposi sarcoma 1.91 2.05E-13 537 9 19 
 
 
pancreas neuroendocrine 
carcinoma 
1.40 2.75E-06 386 5 10 
 
 
MEN1, 
RET 
kidney nephroblastoma 1.26 5.98E-06 428 5 10 
 
WT1 
small intestine neuroendocrine 
carcinoma 
0.98 1.19E-09 1154 10 21 
 
 
 
hematopoetic and 
reticuloendothelial 
system 
myelosclerosis 0.69 2.75E-09 2186 14 28 
 
 
 
 
vulva and vagina squamous cell 
neoplasms and 
carcinoma 
 
0.63 1.37E-10 3092 17 36 
 
 
 
 
mesothelium mesothelioma 0.62 3.49E-06 1750 10 20 
 
BAP1 
breast mucinous and 
mucinous cystic 
tumor 
0.57 2.45E-07 2564 13 27  
*
Poisson distribution;
**
with lower confidence limit
 
(CI-low) ≥10 
also showed striking aggregation to western Finland, with another aggregate in northeastern 
Finland (Figure 4C). To test if this was due to uneven distribution of HHV8 infection in Finland, 
we studied seroprevalence of HHV8 from 200 age and gender matched non-KS affected 
individuals from eastern and western Finland. The overall HHV8 seroprevalence was 1% (n=4), 
with two of the seropositive cases originating from Eastern and two from Western Finland, 
indicating equal distribution of the HHV8 infection between Eastern and Western Finland. 
However, due to low number of positive cases the result remains suggestive. 
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Figure 4. Geographical distribution of Kaposi sarcoma (KS) in Finland. (A) Clustered KS patients in 
Finland to whom we were able to confirm true kinship; each flag marks one KS patient; red and blue flags 
represent the lower confidence limit (CI-low) of MN-clusters, black denotes patients in N-cluster. (B) All 
other KS patients belonging to MN- and N-clusters in Finland. (C) The observed/expected (O/E) ratios of 
KS incidence according to municipality of birth; the largest cities are denoted with a circle with a diameter 
relative to expected number of cases and the color indicates the O/E; white stripes denote sparsely 
populated areas of Finland with <1 inhabitant per km
2
. Borders of Finland are based on those before year 
1940 since many of the KS cases were born prior to that. 
2. STAT4 as a candidate susceptibility gene for Kaposi sarcoma 
In study II, we studied the possible genetic predisposition in the Finnish cKS family with five 
affected individuals in two generations, originally identified as a part of study I. To exclude the 
chromosomal regions that were not shared by the affected family members, we performed 
genome-wide genotyping of the cousins (III-5 and III-6; Figure 1), followed by linkage analysis 
with dominant inheritance model. The chromosomal regions with negative LOD score and that 
were less than 1cM in length were considered not to be shared, and were excluded from further 
consideration. This resulted in 1350 cM, or 1.23 Gbp of shared chromosomal regions. The 
longest shared region was 89.7 cM in length and it was located at chromosome 2q14.2-2q35. 
To identify the genomic variants that were located within the linked regions, we sequenced the 
genomes of the index and the affected cousin. After excluding intronic and non-synonymous 
coding variants, altogether 2646 shared protein coding variants remained. Subsequent filtering of 
common polymorphisms (MAF>0.005 in 242 control genomes) reduced the list of shared 
candidate variants into 26, of which 14 segregated in the exome of the index case’s sister (III-2; 
Figure 1 and Table 5). We also considered the structural variants (SVs) that the index case and 
the cousin shared, and we identified altogether 362 shared SVs, but none remained after filtering 
against the segmental duplications and the HiSeq Depth regions and the SVs present in the 
genomes of 49 in-house controls. 
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2.1 Prioritization of the candidate variants 
Due to restricted sample materials, we were not able to study the segregation of the remaining 14 
candidate variants in all five affected individuals in the family. Since immunity plays a central 
role in the development of KS we decided to concentrate on the candidate variants with known 
human immunity related functions. Among the 14 candidates, 3 resided in genes with known 
human immunity related functions including p.Val36Met in HLA-C, p.Pro212Ala in HLA-DRB5 
and p.Thr446Ile in STAT4. In silico prediction was used to study the putative effect of these 
variants. The variant in HLA-DRB5 was predicted benign, whereas the variants in HLA-C, and 
STAT4 were predicted to be damaging. Further search of these variants the public variant 
databases showed that the HLA-C variant (rs2308538) was not listed in the Exome Variant server 
or in the 1000 Genomes database, but it was found to be present with a relatively high population 
frequency in the dbSNP (MAF=0.2, dbSNP; build 134). The rs2308538 was also reported to map 
to seven alternative alleles of the human reference genome. The STAT4 variant (rs141331848) on 
the other hand, was shown to be a very rare variant with global MAF of 0.0005 in the dbSNP as 
well as with MAFs of 0.001 and 0.0025 in the 1000 Genomes and Exome Variant server, 
respectively. We studied its presence in 180 population-matched blood donor controls originating 
from the same geographical region as the KS family and detected no variant carriers.  
The c.1337C>T substitution encodes a missense change altering the amino acid 446 of STAT4 
from threonine to isoleucine (p.Thr446Ile). Threonine 446 is a highly conserved amino acid in 
evolution and it is located within the DNA binding domain of STAT4 (see Figure 2B and C in the 
original manuscript, study II). The c.1337C>T substitution is also located two nucleotides from 
the 3’ exon-intron boundary of the exon 16 in the STAT4 (CCDS2310) and thus we hypothesized 
that it may affects the mRNA splicing of STAT4. We studied the possible splicing defect of the 
STAT4 by cDNA sequencing, but the splicing was shown to be not affected. 
Table 5. The segregating variants in the Finnish KS family 
Gene Genomic 
position 
Nucleotide 
Change 
Amino acid 
change 
Genotype rs-code In healthy 
controls 
(n=242) 
RANBP2 2:109374917 C->T His839Tyr Het - 0 
CYP4F31P 2:132044787 G->A Val36Met Het rs112500726 1 
STAT4 2:191904022 G->A Thr446Ile Het rs141331848 0 
C3orf52 3:111835543 G->A Glu151Lys Het rs201307291 2 
MUC4 3:195512212 G->T Pro2080His Het rs75588776 0 
NUDT6 4:123814164 G->A Thr257Ile Het rs45606640 1 
SLC7A11 4:139106315 A->G Ile292Thr Het rs144628608 0 
CARD6 5:40843521 G->A Gly184Glu Hom and 
Het 
rs186662969 2 
HLA-C 6:31239613 C->T Val36Met Het rs2308538 1 
HLA-DRB5 6:32487165 G->C Pro212Ala Het rs142204283 1 
MS4A10 11:60565924 T->C Val220Ala Het rs139578350 2 
MTMR10 15:31233884 T->C Tyr708Cys Het rs200560796 0 
SPTBN5 15:42170634 G->A Arg1126Cys Het rs200015124 0 
ADAMTS1 21:28210069 C->A Gln911His Het rs200480524 0 
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Genomic positions are described based on the reference build GRCh37/hg19; rs-codes are from dbSNP 
Build 139. Het denotes heterozygous and Hom homozygous. 
2.2 STAT4 activation is not affected by p.Thr446Ile mutation 
To see if the p.Thr446Ile mutation affected STAT4 function, we induced naive and memory 
CD4+ T cells of the mutant and wild-type STAT4 carriers using IL-12 or IFN-. We analyzed 
the activated cell populations from four STAT4 p.Thr446Ile carriers and eight age- and sex-
matched wild-type controls by flow cytometry, using antibody against phosphorylated STAT4 
(pY693). Comparable amounts of phosphorylated STAT4 were detected in the mutants and in the 
healthy controls, indicating that the heterozygous p.Thr446Ile mutation does not affect the 
phosphorylation of STAT4 (Supplementary data, Figures 1B and C of the manuscript, study II).   
2.3 IFN-  production is decreased in the p.Thr446Ile variant carriers 
Next, we tested, if the IFN--responses of the mutant carriers were affected. IFN- staining 
intensity, following PMA and ionomycin stimulation, was significantly decreased in the naive 
CD3+CD8- T helper (Th) cells of the p.Thr446Ile variant carriers (Figure 3B of the manuscript, 
study II). Similar trend, although not statistically significant, was also present in the memory 
CD3+CD8-Th cells of the p.Thr446Ile variant carriers (Figure 3B of the manuscript, study II). 
No differences were found in the percentages of IFN--positive cells, however (see Figure 3A of 
the manuscript, study II). The IFN- responses were also measured in the CD8+ cytotoxic T cells 
of the p.Thr446Ile variant carriers and wild-type subjects, but the responses remained at 
comparable levels (Figure 3B of the manuscript, study II). 
2.4 IL-4 and IL-17 responses in the p.Thr446Ile carriers 
We also assessed the IL-4 (a marker for Th 2 cells) and IL-17 (a marker for Th 17 cells) 
expression in the PMA and ionomycin stimulated CD4+ T cell populations and CD8+ T cells of 
the variant carriers and the wild-type individuals by intracellular flow cytometry. Similar 
amounts of IL-4 and IL-17 were observed in the naive and memory CD4+ T cell populations in 
both groups. In the CD8+ T cells, the expression of IL-4 and IL-17 remained at negative or very 
low level, with no detectable differences between the study groups. 
2.5 Screening of STAT4 and associated genes 
To genetically validate STAT4 as a KS predisposing gene, we analyzed the protein coding region 
of STAT4 from the exomes of seven affected KS patients from six Finnish KS families, but did 
not identify any coding mutations. We also screened, by Sanger sequencing, the entire coding 
region of STAT4 from 27 familial cKS patients, from Italy (n=26, belonging to 13 families) and 
Israel (n=1), but identified only common intronic variants. In addition to this, we sequenced the 
c.1337C>T variant site from 56 sporadic Finnish KS tumors samples. Two of the tumors 
harbored a rare synonymous coding variant (c.1338C>A, p.Thr446Thr; rs144421302) variant. 
Although the variant encodes a synonymous change it is also located at a putative splice site of 
the exon 16 of STAT4. The variant listed in public databases, and it is present in the Exome 
Variant Server and NCBI dbSNP with MAFs 0.0025 and 0.002, respectively. 
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Since we did not identify additional STAT4 protein code altering variants, we hypothesized that 
KS susceptibility variants could also be identified from STAT4 related genes. We generated a list 
of STAT4 interacting, regulating or regulated genes (n=47, Supplementary Table 2 of the original 
manuscript, study II) through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenyuity), and studied the exomes of the seven 
Finnish familial KS cases for mutations in these genes. Rare coding variants (MAF<0.01) were 
identified in TYK2 and CCR5 (Table 6). We validated these by Sanger sequencing and their 
segregation was studied in the affected family members in respective families, and only the 
p.His289Arg variant in CCR5 was identified to segregate with the KS in the family of two 
affected siblings. The variant is in silico predicted to be damaging, and it is located within a 
putative transmembrane region of CCR5. 
 Table 6. Variants in STAT4 related genes 
Gene Genomic 
position 
Nucleotide 
change 
Amino acid 
change 
Genotype rs-code In healthy 
controls 
(n=242) 
CCR5 3:46415259 A->G His289Arg Het - 0 
TYK2 19:10472967 G->A Arg548Cys Het - 0 
TYK2 19:10478867 C->T Arg110Gln Het rs56090991 0 
Genomic positions are described based on the reference build GRCh37/hg19; rs-codes are from dbSNP 
Build 139. Het denotes heterozygous. 
3. NPAT may predispose to nodular lymphocyte predominant Hodgkin 
lymphoma  
3.1 Analysis of large chromosomal alterations and EBV-infection 
In study III, a Finnish family with four NLPHL affected cousins (Saarinen et al., 2011) was 
studied for a genetic predisposition. The possibility of a larger chromosomal alteration as the 
cause of NLPHL predisposition was excluded by standard G-banding from the index case (III-1; 
NLPHL-family, Figure 2), whose karyotype was shown to be normal. The tumors of the affected 
individuals were also tested for presence of EBV, by EBV-encoded RNA in situ hybridization, 
but no sign of EBV was detected.   
3.2 Identification of NPAT as a candidate susceptibility gene 
To identify putative predisposition genes, we performed genome-wide linkage analysis followed 
by exome sequencing. Genome-wide SNP genotypes were produced from all family members of 
the NLPHL family from whom genomic DNA was available. Next, we performed a parametric 
linkage analysis with ‘affected only’ approach. Thirteen genomic regions, spanning 112 
Megabases (Mb) of the genome, segregated with NLPHL in the family (Table 2 of the original 
article, study III). The regions were fine-mapped with microsatellite markers, but none of the 
regions could be excluded based on this.  
To identify the protein code altering variants in genes that resided within the linked regions, the 
index cases’s germline was exome sequenced (III-1; Figure 2). After combining the variants from 
the exome with the linked regions, we removed all synonymous, intronic, and bad quality 
variants as well as the variants present in 13 in-house control exomes. This resulted in 14 
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heterozygous candidate variants. These were further confirmed by Sanger sequencing, and half of 
the variants were shown to be false positive calls. Of the remaining seven variants, six segregated 
in all four affected family members (Table 7). These were studied in additional Finnish blood 
donor samples, and the only variant that was not present in the controls was a heterozygous 
frameshift mutation (c.2437-2438delAG) in the nuclear protein, ataxia-telangiectasia locus 
(NPAT) (Table 7). The mutation destroys the reading frame and putatively creates a premature 
stop codon after five encoded amino acids (p.Leu814Phefs*5).  
We further studied the presence of the c.2437-2438delAG NPAT mutation in seven unaffected 
family members (II-2, II-3, II-6, II-7, II-11, III-3 and III.15; Figure 2), and five were shown to 
carry the deletion. Three of the carriers were mothers of the affected individuals and thus they 
were obligatory carriers of the deletion. The other two mutation carriers were monozygotic twin 
aunts of the affected individuals (II-6 and II-7; Figure 2).  
Table 7. Exomic variants segregating with nodular lymphocyte predominant Hodgkin lymphoma in the 
Finnish family of four affected individuals 
Gene Genomic 
Position 
Nucleotide 
Change
 
Amino acid 
Change 
Genotype rs-code
 
In healthy 
controls 
SLC22A14 3:38349147 delTGTT p.Leu238Serfs* Het rs138257211 1/3 
NPAT 11:108043273 delCT p.Leu814Phefs* Het - 0/239 
KRT85 12:52758810 C>T p.Asp189Asn Het rs112554450 1/3 
DGKA 12:56334185 A>G p.Thr296Ala Het rs141417048 2/110 
MIP 12:56848079 C>T p.Val107Ile Het rs74641138 2/3 
POF1B X:84569452 G>A p.Arg315Cys Hom rs76123916 2/251 
Genomic positions are described based on the reference build GRCh37/hg19; rs-codes are from dbSNP 
Build 139. Het denotes heterozygous and Hom homozygous. 
 
3.3 Expression of NPAT in the c.2437-2438delAG carriers 
NPAT expression was studied from 8 mutation carriers and 12 controls by transcriptome analysis. 
The expression was shown to be reduced in the mutant carriers (fold change 0.80, p=0.016). This 
was validated by NPAT cDNA sequencing from nine NPAT c.2437_2438delAG carriers and two 
NPAT wild-type family members. The mutant allele peaks in all nine mutation carriers showed 
lowered peak intensities of the mutant allele (Figure 5). NPAT cDNA was also screened from 
NLPHL-derived DEV cell line as well as from the cDNAs of two previously reported NLPHL 
families (Campbell et al., 2004; Bauduer et al., 2005), but no mutations were identified. 
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Figure 5. cDNA of 
NPAT wild-type 
individual and 
cDNA and genomic 
DNA of 
heterozygous NPAT 
c.2437-2438delAG 
mutation carrier. 
The reduced 
expression of the 
mutant allele can be 
seen in the cDNA 
of the mutation 
carrier.  
 
3.4 In-frame deletion of p.Ser725 in Hodgkin lymphoma 
To find additional patients with NPAT mutations, we screened the entire coding region and exon-
intron boundaries of NPAT from 73 Finnish and 93 UK HL cases. A rare in-frame deletion 
(c.2171_2173delCTT), which deletes the serine at the amino acid position 725 (p.Ser725del) was 
identified from one Finnish NLPHL case and from six HL cases from UK. The Finnish NLPHL 
case was an early onset NLPHL patient, diagnosed at the age of 21. Four of the UK cases were 
also early onset NLPHL patients, diagnosed before the age of 30. The other two UK cases had a 
first degree relative with non-HL and HL, respectively. We studied the frequency of the deletion 
in the available healthy Finnish an UK control samples. Two Finnish and three UK controls were 
found to carry the deletion. On the basis of the observed p.Ser725del carriers, an odds ratio for 
p.Ser725del and HL was calculated. Odds ratio of 4.11 (with 95% CI, 1.27-13.35, p=0.018) was 
observed, suggesting an increased risk of HL in the mutant carriers.  
4. Loss-of-function mutation in SUFU in meningioma predisposition 
4.1 NF2 is not associated with the Finnish meningioma family   
In study III, we aimed to identify the possible genetic cause of the intracranial meningiomas in a 
Finnish family with five affected individuals. The index case (II-13; Figure 3) of the family was 
directed to genetic counseling after his third meningioma operation. His four sisters (II-2, II-5, II-
9 and II-12; Figure 3) had also had meningiomas. Three out of the four sisters (II-2, II-5 and II-12; 
Figure 3) had had multiple meningiomas and one had had (II-9; Figure 3) a solitary meningioma.  
Because multiple neoplasia syndrome Neurofibromatosis, type II, NF2 (MIM #101000) is 
associated with increased risk of meningiomas, the index case was examined for germline 
mutations in NF2 at the medical genetics clinic by Sanger sequencing and multiplex ligation-
dependent probe amplification. However, no NF2 mutations were detected. We also confirmed 
by transcriptome analysis that the patients and the control subjects had comparable expression of 
NF2 (fold change=0.99) in the blood.  
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To explore the possibility that a larger copy number gain or loss would cause the meningioma 
susceptibility, we performed array comparative genomic hybridization from four affected family 
members. The studied individuals shared altogether 18 copy number alterations, but these were 
all shown to have multiple entries in the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home) and were thus not considered to be relevant for the 
meningioma predisposition (Table 8).  
Since about 60% of sporadic meningiomas harbor somatic NF2 mutations (Louis et al., 2007), 
we wanted to see if the tumors from the affected family members also harbored somatic NF2 
mutations. We Sanger sequenced the entire coding region and the exon-intron boundaries of NF2 
were from the seven available meningiomas belonging to four affected individuals, but identified 
no NF2 mutations, indicating that the meningiomagenesis in the family was not related to NF2.  
4.2 Identification of meningioma susceptibility genes  
To identify novel meningioma susceptibility alleles, a combination of genome-wide SNP 
genotyping, linkage analysis and exome sequencing was used. Owing to the family structure 
(Figure 3), nonparameteric linkage analysis was performed. The linkage analysis resulted in 174 
chromosomal regions with positive LOD scores and with a total length of 1.3 Gbp of shared 
genomic regions (online supplement, Table S1 of the original article, study IV).  
To study the genetic variants residing in the linked regions, we sequenced the germline exomes 
of three affected family members (II-2, II-5 and II-13; Figure 3). All synonymous coding variants, 
variants present in the 78 in-house control exomes, listed in dbSNP (v.132), and variants located 
outside the linked regions were excluded from further consideration. As a result, 20 protein code 
altering candidate variants remained (Table S2 of the original article, study IV). The segregation 
of these was further studied by Sanger sequencing in all affected individuals, and seven 
heterozygous missense mutations were found to segregate with the meningiomas in the family 
(Table 9).  
Next, we studied the presence of these 7 variants in a set of 188 healthy Finnish blood donor 
samples and samples from healthy family members. Three of the variants were found to be 
present in the controls and two were found from unaffected siblings, resulting in two potential 
heterozygous candidates, the c.1990A>G (p.Ser664Pro) in AASS and the c.367C>T 
(p.Arg123Cys) in SUFU (Table 9). To assess the putative impact of the AASS p.Ser664Pro and 
the SUFU p.Arg123Cys, we performed in silico predictions with Polyphen2 (Adzhubei et al., 
2010) and SIFT (Kumar et al., 2009). Both programs predicted the p.Arg123Cys SUFU mutation 
to be damaging (Figure 6A) and the AASS p.Ser664Pro to be benign. Multiple sequence 
alignment also showed that the arginine 123 of SUFU is highly conserved in evolution (Figure 
6B). We then studied the presence of possible loss of heterozygosity (LOH) at the site of the 
SUFU and AASS variants. LOH was observed at the site of the SUFU mutation in all of the seven 
studied tumors but no LOH was observer at the site of the AASS mutation. 
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Table 8. The copy number alterations in the Finnish meningioma family 
Region Patients Chromosome Start bp
 
End bp
 
No of 
markers 
CNV 
1 II-13 1 72539172 72579340 14 Loss 
II-2, II-5, II-12 1 72539172 72579340 14 Loss 
2 II-13 1 150836504 150851468 10 Loss 
II-2, II-5, II-12  1 150823099 150852881 12 Loss 
3 II-13 1 157134825 157136371 2 Loss 
II-2, II-5, II-12 1 157134825 157136371 2 Loss 
4 II-13 1 195062822 195150019 28 Loss 
II-2, II-5, II-12 1 195022883 195150019 31 Loss 
5 II-13 2 33619289 33621140 2 Loss 
II-2, II-5, II-12 2 33619289 33621140 2 Loss 
6 II-13 3 163997257 164027753 8 Gain 
II-2, II-5, II-12 3 163997257 164107980 28 Gain 
7 II-13 5 12866067 12873081 2 Loss 
II-2, II-5, II-12 5 12866067 12873081 2 Loss 
8 II-13 5 97074093 97119405 7 Loss 
II-2, II-5, II-12 5 97060234 97126947 9 Loss 
9 II-13 6 32563281 32600991 9 Loss 
II-2, II-5, II-12 6 32558699 32600991 10 Loss 
10 II-13 7 133436294 133448306 8 Loss 
II-2, II-5, II-12 7 133436294 133448306 8 Loss 
11 II-13 7 141698663 141714197 10 Gain 
II-2, II-5, II-12 7 141700461 141714197 9 Gain 
12 II-13 10 114103576 114106489 2 Loss 
II-2, II-5, II-12 10 114103576 114106489 2 Loss 
13 II-13 13 33033934 33042586 3 Loss 
II-2, II-5, II-12 13 33033934 33042586 3 Loss 
14 II-13 14 105602631 105632197 12 Loss 
II-2, II-5, II-12 14 105602631 105632197 12 Loss 
15 II-13 16 57204888 57206801 2 Loss 
II-2, II-5, II-12 16 57204888 57206801 2 Loss 
16 II-13 19 51316683 51319033 3 Loss 
II-2, II-5, II-12 19 51316683 51319033 3 Loss 
17 II-13 20 1511661 1531191 9 Loss 
II-2, II-5, II-12 20 1511661 1531191 9 Loss 
18 II-13 22 22677988 22725329 22 Gain 
II-2, II-5, II-12 22 22677988 22725329 22 Gain 
Start bp and End bp are based on the human reference build NCBI36/hg18. Patient numbers refer those in 
Figure III. 
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Table 9. Exomic variants segregating with meningiomas in the Finnish family of five affected individuals  
Gene Genomic 
position 
Coding 
nucleotide 
Amino acid 
change 
In 
controls 
 
In unaffected 
family 
members
 
rs-code
 
CTRC 1:15772126 c.697A>C p.Glu225Ala 0/187 Yes rs201486613 
ZNF80 3:113955753 c.673C>T p.Val57Met 0/182 Yes rs146464395 
AASS 7:121731783 c.2135A>G p.Ser664Pro 0/174 No rs202247760 
SUFU 10:104309776 c. 367C>T p.Arg123Cys 0/180 No rs202247756 
IFIT2 10:91067047 c.1509A>G p.Lys445Arg 3/69 nd rs138979563 
KL 13:33628244 c.1168G>A p.Arg387His 1/90 nd rs200112661 
SERPINA12 14:94953767 c.1914G>A p.Ala373Val 1/89 nd rs138209155 
Genomic positions are based on the human reference genome build GRCh37/hg19; rs-codes are adopted 
from the dbSNP Build 139, nd: not determined. 
 
 
Figure 6. In silico assessment of p.Arg123Cys SUFU mutation (A) Polyphen2 prediction of the 
p.Arg123Cys mutation. (B) Multiple sequence alignment of SUFU. The p.Arg123 is marked with an 
arrow. Blue, red and green color denotes hydrophobic, negative, and positive amino acids, respectively.  
 
4.3 In silico modelling of the p.Arg123Cys SUFU mutation  
To investigate effect of the p.Arg123Cys SUFU mutation further, we performed three-
dimentional modelling of the mutant and wild-type SUFU using Crystallographic Object 
Oriented Toolkit (COOT, Emsley and Cowtan, 2004). This implicated that the arginine 123 is 
located in the center of the N-terminal subdomain of SUFU and that it forms multiple hydrogen 
bonds and ionic interactions with histidine 89, aspartic acid 182 and glutamines 184 and 199 
(Figure 7A). These interactions are central for the loop structures of the N-terminal subdomain of 
SUFU. When the arginine 123 is substituted by cysteine, the interactions are lost and the loop 
structures are relaxed, possibly affecting the proper tertiary structure of SUFU (Figure 7B).    
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Figure 7. Computational modelling of the SUFU p.Arg123Cys mutation. 
(A) Ribbon representation of wild-type SUFU. The p.Arg123 and the interacting residues are illustrated as 
balls and sticks. Dashes represent hydrogen bonds and ionic interactions. The secondary structure 
elements are labeled in accordance to Merchant et al., 2004. (B) The p.Arg123Cys mutant SUFU. All 
hydrogen bonds and ionic interactions are lost possibly interfering with the formation of the proper tertiary 
structure of the protein and thus its function.   
4.4 Mutated SUFU leads to dysregulated Hedgehog signaling  
To elucidate the properties of the p.Arg123Cys SUFU mutation in vitro, we studied its ability to 
suppress GLI1 in human rhabdomyosarcoma cells (CRL-2061). These cells have constitutively 
activated Hedgehog signaling (Hh) pathway due to 30-fold amplification of GLI1 (Roberts et al., 
1989). The cells were transfected with the mutant or wild-type SUFU expression construct with 
Hh-specific reporter plasmid and a control reporter plasmid. The luciferase activity was measured 
after 2-3 days of incubation. The assays were conducted with and without ShhN-conditioned 
medium in duplicate and were repeated at least three times. The relative luciferase activity was 
calculated by dividing the firefly luciferase counts by the Renilla luciferase counts. Compared to 
the wild-type SUFU, the mutant SUFU had significantly reduced ability to suppress Hh activity 
(Figure 8A). Comparable results were obtained also when the same experiments were performed 
in Sufu knock-out (Sufu -/-) MEFs (Figure 8B).  
SUFU is known to directly interact with GLI1 and regulate its shuttling from nucleus to 
cytoplasm (Kogerman et al., 1999). To test if the reduced suppressive activity of the mutant 
SUFU was due to impaired interaction with GLI1, we tested their interaction in the mutant and 
wild-type SUFU transfected CRL-2061 cells with a pull-down immunoblot analysis using 
primary antibodies against Myc-tagged SUFU and GLI1. Compared to the wild-type SUFU, the 
protein level of the p.Arg123Cys SUFU was decreased and it was found to bind clearly less GLI1 
(Figure 8C). 
To further elucidate if the p.Arg123Cys mutation affected the subcellular localization of GLI1, 
we transfected CRL-2061 cells and Sufu-/- MEFs with Myc-tagged wild-type and mutant SUFU 
expression plasmids. The cells were incubated two days with or without ShhN-conditioned 
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medium after which they were stained with antibodies against GLI1 and Myc-tagged SUFU. In 
the mutant SUFU transfected cells, GLI1 was localized more in the nuclei, indicating impaired 
re-localization of GLI1 to the cytoplasm (Figure 9).   
 
 
Figure 8. The p.Arg123Cys mutated SUFU has reduced suppressive activity and impaired binding of 
GLI1. (A) Human rhabdomyosarcoma cells (CRL-2061) or (B) Sufu knockout (Sufu-/-) mouse embryonic 
fibroblasts (MEFs) were transfected with wild-type or mutant SUFU constructs, Hedgehog pathway 
specific reporter plasmid and control reporter plasmids. The cells were incubated with and without ShhN-
conditioned media and luciferase activity was measured. 
*
t-test p<0.05 compared to Myc-hSUFUWT. 
Error bars denote one standard deviation (duplicate samples). (C) The p.Arg123Cys mutant SUFU has 
reduced binding of GLI1. GLI1 binding in relation to Myc-SUFU protein level is shown below the panel.  
 
4.5 Screening of SUFU in additional meningioma samples 
To identify additional SUFU mutated patients, we Sanger sequenced the exons and exon-intron 
boundaries of SUFU from 162 meningioma-affected individuals, including 4 NF2 mutation 
negative individuals with multiple meningiomas, 77 Finnish meningioma cases from the 
Interphone case-control study (Interphone Study Group, 2010), 35 individuals from the UK with 
multiple meningiomas, 5 familial UK meningioma cases, and 41 meningioma tumors collected 
through the Finnish Cancer Registry, but did not find any pathogenic mutations. Since SUFU is a 
known predisposition gene in childhood medulloblastoma (Taylor et al., 2002), we also screened 
the c.367C>T mutation site from a distant relative of the Finnish meningioma family who had 
died of medulloblastoma at the age of 5. We screened the mutation site from DNA extracted from 
two different FFPE samples, but detected no SUFU mutations. 
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Figure 9. The p.Arg123Cys SUFU mutation impairs the re-localization of GLI1 from nucleus to cytoplasm in 
CRL-2061 and SuFu (-/-) mouse embryonic fibroblasts. 
54 
 
DISCUSSION 
1. Familial aggregation of tumors in Finland  
Cancer, like many other complex diseases, occurs mostly sporadically, but a small fraction of 
cases display familial inheritance. One aim of this study was to assess the familial aggregation of 
cancers in Finland. To meet this aim, we utilized the population-level information on Finnish 
inhabitants and cancer patients in the National Population Registry (NPR) and the Finnish Cancer 
Registry (FCR) databases, respectively. Both registries have high coverage and high quality data 
and use personal ID codes for unique identification, which enables linking of the data in the two 
registries (Pukkala, 2011). 
NPR was established in 1969, and together with the local register offices it maintains and 
controls the data on Finnish citizens (http://www.vrk.fi). However, the bookkeeping of the 
inhabitants in Finland dates back to the 16
th
 century and from 1660 onwards the Church Parish 
Registries have kept records of Finnish inhabitants on a national level, enabling extensive 
genealogy work and ancestry identification of individuals back to the 17
th
 century. The ID code 
system in Finland was implemented in the 1960s and since 1967 a unique 11-digit ID code has 
been in use. 
FCR is a population-level patient database, and it currently contains information on more than 1 
million patients. FCR was founded in 1952 and it is one of the first nation-wide cancer registries 
in the world. The registration of incident cancers was made obligatory by law in 1961 and FCR 
covers almost all cancers in Finland since 1953 (Teppo et al., 1994). In addition to cancer 
diagnoses, FCR collects information about the hospitals, laboratories and diagnostic samples of 
the patients. FCR is also an active research institute and produces the yearly cancer statistics in 
Finland (www.cancer.fi).  
Because individuals with same family name and birth place are likely to be related, we used 
family name at birth and municipality at birth based clustering (MN-clusetring) to assess the 
aggregation of cancers in Finalnd. To take into account the possible migratory events of the 
families we performed another clustering based on the tumor type and family name at birth only 
(N-clustering). Similar method has been employed by Matikainen et al. in 2000 to identify novel 
prostate cancer families (Matikainen et al., 2000).  
In contrast to many traditional epidemiological tools, our method can be used to study familial 
aggregation of both rare and common tumor types. The two systematic clustering efforts, that we 
performed yielded altogether 25 910 municipality-name based clusters and 12 695 name-based 
clusters, represented 183 different tumor types, which is considerably more than what previous 
studies on familial aggregation has been able to cover (Goldgar et al., 1994; Amundadottir et al., 
2004; Albright et al., 2012). The most commonly clustered tumor type was basal cell carcinoma 
of the skin, which was an expected result since it is the most common cancer in humans and the 
most registered tumor type in FCR. 
When we ranked the different tumor types based on the cluster score, reflecting the frequency of 
cluster formation in relation to the incidence of a given tumor type in Finland, four out of five top 
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ranking tumor types represented tumors commonly seen in patients with hereditary cancer 
syndromes. The number one scoring tumor type was hemangioblastoma, which is a vascular 
tumor, most commonly affecting the nervous system. Hemangioblastomas occur frequently in 
patients with Von Hippel-Lindau syndrome (MIM #93300), caused by germline mutations in 
VHL. The second tumor type in our cluster score ranking list was medullary thyroid cancer. It is 
often seen in patients with multiple endocrine neoplasia 2A (MIM #171400) or 2B (MIM 
#162300) (Nose, 2011). The third most frequently clustered tumor type was KS, which is a soft 
tissue sarcoma with infectious etiology and unknown genetic predisposition (discussed in more 
detail in the next section). The fourth and fifth tumor types were pancreatic neuroendocrine tumor 
and nephroblasoma, indicative of patients with multiple endocrine neoplasia type 1 (MIM 
#131100) and Wilms tumors 1 (MIM #194070), respectively. 
Neuroendocrine carcinoma of small intestine and myelosclerosis also showed strong familial 
aggregation in our cluster score assessment. Increased familial risk for small intestine 
neuroendocrine tumors has been previously reported (Hemminki and Li, 2001; Hiripi et al., 2009; 
Kharazmi et al., 2013), but the genetic etiology remains poorly studied. This is also the case with 
myelosclerosis. Landgren et al. described increased familial risk for almost all other 
myeloproliferative disorders, except for myelosclerosis. This however is most likely due to lack 
of statistical power in their study (Landgren et al., 2008). 
Strong familial clustering of squamous cell neoplasm and carcinoma of vulva and vagina was 
also detected in our data. Increased familial clustering of vulvar squamous cell carcinoma has 
also been previously reported (Hussain et al., 2008). Human papillomavirus (HPV) is a causal 
factor in many anogenital cancers (IARC Working Group on the Evaluation of Carcinogenic 
Risks to Humans, 2012). The familial aggregation data by us and others, does not allow 
concluding whether the observed familial aggregation is caused by shared environmental or 
genetic factors. However in the case of vulvar squamous cell carcinoma, it is likely that the 
familial aggregation reflects factors related to HPV susceptibility, since HPV is mainly 
transmitted sexually. 
From the more common tumor types, with more than 7000 patients in the FCR database, 
papillary thyroid adenocarcinoma, chronic lymphatic leukemia, and squamous cell carcinoma of 
the lip showed the strongest familial aggregation. Familial clustering of the same tumors has been 
previously observed in a study assessing the familial occurence of cancers in the Utah Population 
Database, containing 85 550 cancer patients (Albright et al., 2012). In addition, several other 
studies have described familial aggregation of papillary thyroid adenocarcinomas and reported up 
to 8-10 fold increased risk for relatives of papillary thyroid carcinoma patients (Nose, 2011; 
Bauer, 2013). A number of studies have demonstrated increased familial risk also for chronic 
lymphocytic leukemia (Gunz et al., 1975; Giles et al., 1984; Cartwright et al., 1987; Pottern et al., 
1991; Goldgar et al., 1994; Radovanovic et al., 1994). Despite extensive efforts, no definite high 
risk susceptibility gene has thus far been identified for either one of these tumor types (Goldin et 
al., 2010; Nose, 2011).  
Since our clustering method has been developed to identify cases with similar disease, or other 
phenotypic feature, that share common birth place and birth name, it could in principle be used to 
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study familial aggregation of any other registered disease. The only requirement is that 
information on family names and birth places of the patients are available, while population-level 
data is required for statistical assessment of the clusters. Also, for the method to be able to 
identify statistically significant clusters, the family names in the study population should contain 
enough variation.   
In Finland, the family names are generally inherited from father and thus our clustering method is 
restricted to identify siblings or families from the paternal side only. The method would heavily 
benefit from readily available genealogy data, like that available for example at the deCODE 
genetics in Iceland, the Swedish Family-Cancer Database in Sweden, or Utah Population 
Database in Utah, USA. A small pedigree, including the first degree relatives and children of 
siblings, could in principle be constructed based on the family data available in NPR, for almost 
all inhabitants in Finland. However, these data has limited coverage, covering only individuals 
born after 1967, or who were alive at that time, enabling the automatic pedigree formation only 
for a fraction of cancer cases in FCR.  
1.1 Identification of potential tumor susceptibility families 
This study also aimed to identify novel cancer families for subsequent research on genetic 
predisposition. As described above, the clustering data provides thousands of potential cancer 
families for further genetic analyses. KS, which produced significant MN-clusters third most 
commonly, was chosen as an example tumor type to study how well the method actually can 
predict true cancer families. We performed thorough genealogy work for all MN-clustered KS 
cases, resolving the family pedigrees at least three generations back. True relationships were 
confirmed for 70% of the individuals in MN-clusters. When we considered only the clusters with 
high statistical significance (CI-low ≥10), 88% of the clustered cases were found to be related. 
Although it seems that the significance of the cluster can quite well predict true relation of the 
clustered individuals, a large amount of manual work is needs to be done to actually confirm 
them, and here again the presence of a nation-wide pedigree database would be an excellent 
resource.  
The NLPHL family and the meningioma family examined in studies III and IV were originally 
observed by medical geneticists Kristiina Aittomäki and Pia Alhopuro, respectively. After 
thorough examination and genetic counselling, they were directed to us for further studies on 
genetic predisposition. This happened before study I was conducted, but in principle, both of the 
families could have been identified through our FCR clustering effort. Later examination of the 
clusters indeed revealed a MN-cluster of five meningioma patients (p-value 0.06 O/E 26 and CI-
low 188) representing the meningioma family, while clusters representing the NLPHL family 
could not be detected. There are two possible reasons for this. Firstly, the mothers of the affected 
NLPHL cases had taken their spouses family names in the marriage, and thus the affected cousins 
did not share same family names. Secondly, the two affected brothers, who shared the family 
name, who should have formed MN- or N-cluster, had different lymphoma diagnoses (lymphoma, 
not otherwise specified [NOS] and Hodgkin disease) in the FCR, leading them to fall into two 
different tumor classes.  
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The NLPHL family example reflects the problematic and variable diagnosing of lymphomas, 
especially NLPHL, but it also reflects the difficulty of defining meaningful tumor classes for the 
clustering. The ICD-O-3 classification, currently in use in the FCR, is very detailed and to enable 
efficient cluster formation we had to re-classify the tumors into larger morphology and 
topography groups. Although this was done carefully, respecting the molecular and pathological 
backgrounds of different ICD-O-3 classifications, certain tumor types such as lymphomas, 
meloproliferative disorders, or hematological diseases might have benefited from less stringent 
grouping.  
2. Kaposi sarcoma in the Finnish population 
Although KS is a rare tumor type in most places in the world, it is the most common tumor in 
HIV-infected individuals and in certain parts of Sub-Saharan Africa (Mesri et al., 2010). HHV8 
is the infectious agent underlying the development of KS, and it is well acknowledged that 
patients suffering from immunosuppressive conditions, or lowered immunity due to 
immunosuppressive drugs, have higher risk for KS (Beral et al., 1990; Mbulaiteye and Engels, 
2006). To date, a little over 100 KS families, including the families identified in study I, have 
been described (Almohideb et al., 2013), and accumulating evidence suggests that host genetic 
factors play an important role in KS development. 
In study I, we observed a significant familial clustering of KS in Finland. KS is a very rare tumor 
type in Finland, with an average incidence of 0.1–0.2 per 100 000 person-years in 1963–2010, 
age-adjusted to the World Standard Population. We showed that the incidence of KS varied 
strongly according to the municipality of birth of the patients, with much less KS cases 
originating from eastern than western Finland. Unequal geographical distribution of KS has also 
been reported in Sweden, where the incidence of KS has been observed to be higher in norther 
parts of Sweden compared to southern parts (Hjalgrim et al., 1996).  
The prevalence of HHV8 varies strongly in different populations, and there seems to be a positive 
correlation between HHV8 prevalence and KS incidence (Tedeschi et al., 2006, Mesri et al., 2010). 
Thus, we hypothesized that the geographical difference in KS incidence in Finland could be due 
to uneven distribution of HHV8 infection. We selected 200 healthy age- and sex-matched 
individuals from Eastern and Western Finland and studied the prevalence of HHV8 in their sera. 
The overall prevalence of HHV8 was shown to be 1%, with two seropositive individuals 
originating from eastern and two from western Finland indicating similar level of HHV8 
seropositivity. However, the result is far from definitive and a thorough examination of HHV8 
seroprevalence in Finland would be important.  
Molecular and serological data suggest that transmission of HHV8 occurs primary via saliva 
(Mayama et al., 1998; Vieira et al., 1997; Vitale et al., 2000; Dupuy et al., 2009) and that the risk 
of HHV8 infection is increased in first degree relatives of classic KS patients (Guttman-Yassky et 
al., 2005; Mancuso et al., 2011). While some of the KS families with two affected individuals 
may be explained by sharing of the HHV8 infection, it is highly unlikely that HHV8 alone could 
explain the KS in a family with as many as five affected cases. 
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2.1. STAT4 and Kaposi sarcoma  
In study II, we concentrated to identify genetic predisposition in the family of five affected 
individuals with classic KS. We mapped the shared choromosomal regions from two affected 
family members and combined the regions with variants identified from the genomes and exome 
sequenced from three affected family members. Because of the viral etiology of KS, we chose to 
use less stringent filtering criteria for the genetic variants and used a MAF cut-off of 0.005% in 
the control genomes (n=242). This led us to identify 14 candidate variants that were present in all 
3 KS affected individuals in the family from whom we had samples.  
Despite many efforts, we were not able to derive samples from all the affected family members, 
and thus and thus the segregation of the 14 candidate variants could not be thoroughly examined. 
The mother of the three affected siblings had died in 1962 and her diagnostic blocks had already 
been destroyed. She, however, is an oblicatory carrier of all the 14 variants. We were also unable 
to derive sample from one of the affected siblings, because her diagnostic blocks were missing. 
Due to the fact that we were not able to study the segregation of all the candicate variants 
completely, we had to rely on more candidate-gene based approach, and we chose to concentrate 
on candidates residing in genes with human immunity related functions including HLA-C, HLA-
DRB5, and STAT4.  
Human leukocyte antigen (HLA) complex alleles have been suggested to be relevant for KS 
predisposition. Especially the HLA-DR5 serotype has been associated with increased risk for KS 
(Papasteriades et al., 1984; Iannidis 1995). The HLA region of the genome is extremely 
challenging to study with the available sequencing methods, because of the high homology of 
HLA genes, and the high variability within the HLA region. Two of our human immunity related 
candidate variants resided in HLA genes. Closer inspection of the variants revealed that the the 
c.106G>A in HLA-C is in fact relatively frequent in the population and that the HLA-DRB5 
variant was not predicted damaging for the protein function. This left the c.1337C>T 
(p.Thr446Ile) in STAT4 to remain as the most prominent human immunity related variant in the 
KS family. The STAT4 c.1337C>T (p.Thr446Ile) varian was in silico predicted to harm the 
correct tertiatry structure of STAT4 and it was absent in the additional 360 Finnish control 
chromosomes examined.  
We studied STAT4 from a relatively large number of familial and sporadic KS cases, but apart 
from a single synonymous change (c.1338C>A, p.Thr446Thr; rs144421302), present in two 
sporadic KS cases, we did not detect any protein code altering variants. We also studied seven 
Finnish familial KS cases for mutations in STAT4 associated genes and identified a novel, 
potentially damaging, heterozygous variant in C-C chemokine receptor type 5  (CCR5, c.866A>G, 
p.His289Arg). CCR5 encodes a chemochine receptor that also acts as a co-receptor of HIV-1 
entry (Deng et al., 1996; Dragic et al., 1996). Individuals with specific CCR5 mutations are 
reported to be resistant to HIV-1 infection (Dean et al., 1996; Liu et al., 1996; Samson et al., 
1996; Kaur et al., 2013). The interaction of STAT4 and CCR5 is not well understood, but STAT4 
has been described to be a negative regulator of CCR5 expression in mouse T cells (Iwasaki et al., 
2001; Watford et al., 2003).  
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STAT4 is located at 2q32.3 and encodes a transcription factor belonging to a family of Signal 
Transducer and Activator of Transcription factors including, STAT1, STAT2, STAT3, STAT5A, 
STAT5B, and STAT6. STAT4 is expressed in the sperm cells, myeloid cells, and T lymphocytes 
and it is activated in response to certain growth factors and cytokines, especially interleukin-12, 
interleukin-23, and type 1 interferons (Takeda and Akira, 2000). Upon activation, STAT4 forms 
dimers and relocates to the nucleus to regulate the transcription of its target genes, especially 
IFN-γ (Zhang and Boothby, 2006; Good et al., 2009). We studied the IFN-γ production in the 
p.Thr446Ile mutation carriers and matched wild-type controls and detected statistically 
significant reduction in IFN-γ levels in the PMA-ionomycin induced naive T helper cells of the 
mutation carriers. Similar trend was also present in the memory T helper cells of the mutation 
carriers. We also studied if the mutation affected the levels of the phosphorylated STAT4, but 
these remained at comparable levels in the mutant carriers and the wild-type individuals.    
The p.Thr446Ile disrupts an evolutionarily highly conserved threonine located in the DNA-
binding domain of STAT4. The DNA binding domains of all STATs, but especially STAT1 and 
STAT4, are highly homologous with over ~60% similarity. Germline mutations in IL-12 receptor 
gene IL-12Rβ1 and STAT1 cause Mendelian susceptibility to mycobacterial disease (MIM 
#209950) (Filipe-Santos et al., 2006). Specific alleles (p.Glu463H and p.ProE320Glu) affecting 
the DNA-binding domain of STAT1, have been reported in otherwise healthy patients with 
mycobacterial disease (Chapgier et al., 2006). Thus it is interesting to speculate whether the 
p.Thr446Ile STAT4 mutation might also be responsible for the index case’s chronic atypical 
mycobacterial infection. 
Stat4 knock-out mice are viable but have severe problems in the IL-12 mediated functions, 
including T helper 1 cell differentiation, IFN-γ production, cell proliferation, and activation of 
natural killer cell cytolytic functions (Kaplan et al., 1996; Thierfelder et al., 1996). Moreover, 
they are susceptible to various intracellular bacteria and pathogens (Kaplan, 2005). A recent 
forward genetics screen discovered a Stat4 DNA-binding domain mutation (p.Gly418_Glu445del) 
in mice susceptible for Acute Typhoid-like disease (Eva et al., 2014). Already the heterozygous 
mutant mice had defective INF-γ mediated immunity, comparable to our cKS family members 
(Eva et al., 2014). In addition to this, a common STAT4 haplotype has been associated with 
susceptibility to certain autoimmune diseases, including rheumatoid arthritis, systemic lupus 
erythematosus and primary Sjögren’s syndrome (Remmers et al., 2007; Lessard et al., 2013). The 
common associated SNP (rs7574865) located within the haplotype has also been associated with 
risk of hepatitis B virus-related hepatocellular carcinoma (Jiang et al., 2013). One report indicates 
STAT4 to regulate the antiviral IFN-γ responses during genital herpes simplex virus 2 infection 
(Svensson et al., 2012). Intriguingly, the p.Thr446Ile STAT4 allele has been detected previously 
from one Finnish individual with high serum IgE levels (Pykäläinen et al., 2005). 
As a summary, we identified 14 possible KS predisposing candidate variants, among them a 
putatively damaging heterozygous missense variant located in the DNA-binding domain of 
STAT4. We provided preliminary evidence that the c.1337C>T STAT4 mutation carriers may 
have defective IFN-γ mediated immunity due to reduced levels of IFN-γ produced by their 
activated CD4+ T cells, but we were not able to genetically validate STAT4 in other KS patients. 
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Based on our data, STAT4 remains as a candidate predisposition gene, and future studies are 
necessary to fully elucidate its role in KS predisposition.  
3. NPAT in Hodgkin lymphoma predisposition 
NLPHL is a rare HL subtype with distinct morphology, immunophenotype, and clinical features 
(Harris et al., 1994). Not much is known about its etiology, and it is a challenging disease to 
study because the patients are so few and because the tumor material is difficult to obtain, since 
the malignant cells in the tumor constitute less than 1% of the cells. High increased risk in the 
first degree relatives of NLPHL patients has recently been reported (Saarinen et al., 2013), and to 
date only five families with NLPHL have been described, including the family examined in study 
III (Saarinen et al., 2011), two families with affected siblings (Campbell et al., 2004; Ur Rehman 
et al., 2008), one family with affected mother and son (Unal et al., 2005), and a family with two 
affected brothers and father (Bauduer et al., 2005). 
To gain insight to the NPLHL predisposition, we performed linkage analysis and exome 
sequencing in the Finnish family of four NLPHL affected cousins. As the only plausible 
candidate, a heterozygous frameshift mutation (c.2437-2438delAG) in nuclear protein, ataxia-
telangiectasia locus (NPAT) was identified. The mutation segregated with the NLPHL in the 
family and was absent in 478 control chromosomes sequenced from 239 healthy Finnish blood 
donors. In addition to the affected family members, the mutation was present in five other 
members of the family, including the oblicate carrier mothers and two aunts, who were identical 
twins. The presence of healthy mutation carriers in such a family indicates incomplete penetrance, 
which is a common feature of hereditary cancer syndromes (Nagy et al., 2004). After the 
publication of study III, however, we learned that one of the unaffected mutation carriers, the 
other twin aunt, had developed diffuse large B-cell lymphoma (DLBCL), which is the most 
common non-HL subtype. NLPHL and DLBCL both derive from B lymphocytes (Campo et al., 
2011), and a small fraction of NLPHLs are known to progress into DLBCL (Al-Mansour et al., 
2010; Biasoli et al., 2010). Also, NLPHL is sometimes difficult to differentiate from a specific 
DLBCL subtype, T-cell/histiocyte-rich large B-cell lymphoma, and thus careful revision of the 
aunt’s diagnosis might be worth conducting (Campo et al., 2011). It would also be interesting to 
screen NPAT, from patients or tumor samples of DLBCL patients to see if it would also underlie 
the development of DLBCL. 
To obtain genetic validation, we screened NPAT from a large set of samples (n=169), including 
NLPHL and HL patients from Finland and UK, as well as the NLPHL derived cell line (DEV). In 
addition to common polymorphisms, an in-frame deletion of serine 725 was identified. The 
deletion was identified altogether from seven patients and five controls. Statistical evaluation 
argued increased risk of HL with the variant (odds ratio 4.11), although this is likely to be an 
overestimation because of the relatively small sample size and enrichment of familial cases in our 
data. Nevertheless, the patients carrying the p.Ser725del in our data had either early onset of 
NLPHL or HL or had family history of lymphomas, indicating possible genetic predisposition. 
Interestingly, the same deletion is listed in the Catalogue of somatic mutation in cancer 
(COSMIC, http://cancer.sanger.ac.uk/cosmic/). COSMIC lists the p.Ser725del to be present in 
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cancer cell lines, originating from kidney (TK10), large intestine (KM12), and lung (NCI-H522) 
(Abaan et al., 2013). As serines are often sites for post translational phosphorylation and since 
NPAT is know to be regulated by phospohorylation (Imai et al., 1996; Ma et al., 2000), it would 
be interesting to study whether the Ser725 would be a site of NPAT regulation. 
We wanted to see if the c.2437-2438delAG mutation affected the expression of NPAT, and we 
performed transcriptome analysis which showed that the expression of NPAT was significantly 
reduced in the mutant carriers. This was also confirmed by cDNA sequencing. We saw a clear 
drop in the mutant allele intensities in all of the studied mutation carriers, suggesting that it was 
degraded by nonsense mediated decay pathway. Messenger RNAs (mRNAs) with premature 
termination codons are often directed to nonsense mediated decay pathway, which is a safety 
mechanism of the cells to destroy of non-functional mRNAs and reduce errors in gene expression 
(Baker and Parker, 2004; Maquat, 2005).  
The great majority (about 90%) of high and moderate risk tumor predisposition genes are tumor 
suppressor genes harboring gene inactivating mutations (Rahman, 2014). The nature of the NPAT 
mutation, supported by its reduced expression, would thus suggest it to be a tumor suppressor 
gene rather than an oncogene. To confirm this, one could have for instance studied the presence 
of ’second hit’ in the tumors of the mutation carriers. However, in the case of NLPHL, this is not 
possible to do by using bulk extracted tumor samples, because the lymphocyte-predominant cells, 
that are the tumor cells, constitute only about 1% of the cells in the tumor (Swerdlow et al., 2008). 
We initially tried to microdissect the lymphocyte-predominant cells from the tumors of the 
affected individuals, but it proved to be extremely difficult to identify the lymphocyte-
predominant cells without appropriate immunohistochemical and morphological stainings.  
NPAT, also known as EI14 or CAND3, is located very close to ATM in the major AT locus on 
human chromosome 11q22-q23 (Imai et al., 1996). The two genes are transcribed to opposite 
directions and separated from each other only by 0.5kb (Imai et al., 1996). Germline mutations in 
ATM cause ataxia-telangiectasia (MIM #208900), which is a recessively inherited disorder 
affecting the nervous and immune systems of the patients. Intriguinly, ataxia-telangiectasia 
patients are in increased risk of getting cancers, particularly B-cell lymphomas and T-cell 
leukemias (Garber & Offit 2005), making it intriguing to consider if the tumorigenic effect of 
NPAT might be associated with ATM. 
Deletion of 11q22-q23, encompassing NPAT and ATM among other genes, is one of the most 
common genetic alterations in chronic lymphocytic leukemias, and the deletion has also been 
detected in many other B-cell malignancies (Coll-Mulet and Gil, 2009). Although ATM is usually 
considered to be the main tumor suppressor gene at the 11q22-q23 locus, biallelic mutations of 
ATM are not always detected, implicating presence of other tumor suppressor genes at the region. 
A study by Kalla et al. described reduced expression of NPAT in chronic lymphocytic leukemia 
patients with monoallelic deletion of 11q22-q23 (Kalla et al., 2007). Another study by Mishra et 
al. reported promoter hypemethylation of NPAT in prostate cancer cell lines, further supporting 
its possible tumor suppressor function (Mishra et al., 2010).  
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NPAT is abundant in most human tissues, and its expression peaks in the G1-S-phase transition of 
the cell cycle (Zhao et al., 1998). NPAT is phosphorylated by the cyclin E-CDK2 complex, 
which also supports its central role in cell cycle progression (Zhao et al., 1998). Overexpression 
of cyclin E is commonly observed in many tumors, including multiple lymphoma subtypes 
(Erlason 1998 Hwang & Clurman 2005). Activation of the cyclin E-CDK2 complex is controlled 
by the Myc and RB/E2F pathways, defected in most of the human cancers (Hanahan and 
Weinberg, 2000). In lymphomas, Myc pathway defects are frequently observed in Burkitt 
lymphoma (Smith et al., 2010), and RB/E2F pathway defects in classical HL (Bai et al., 2005). 
NPAT is also shown to regulate S-phase-specific histone gene transcription together with HINFP 
(Ma et al., 2000; Xhao et al., 2000). In addition to the S-phase-specific histone genes, the 
HINFP-NPAT complex has also been described to activate promoters of non-histone genes, 
including NPAT and ATM (Medina et al., 2007). 
As a summary, NPAT is an important regulator of the cell cycle, and based on the current 
knowledge it can be linked to the development of HL through a number of different mechanisms. 
We identified a truncating NPAT mutation in one NLPHL family, and although higher risk of HL 
was observed in individuals with the in-frame deletion of NPAT Ser725, the date is hardly strong 
enough to validate that the relevance of NPAT in HL. More NLPHL or HL patients, harboring 
germline or somatic NPAT mutations should be identified, and additional experiments conducted 
to confirm the possible function of NPAT in the development of HL. 
4. SUFU, Hedgehog signaling, and meningioma 
Meningiomas are the most common primary tumors affecting the brain and spinal cord 
(CBTRUS, 2012; Wiemels et al., 2010). Although majority of meningiomas occur in isolated 
cases, a small fraction of menigniomas show familial accumulation. A fraction of familial 
meningiomas arise in individuals with Neurofibromatosis type II (MIM #101000), which is an 
autosomal dominant disorder characterized by central and peripheral neural system tumors, 
especially acustic neuromas. A smaller subset appears in patients with familial schwannomatosis 
(MIM #162091), which is an autosomal dominant tumor susceptibility condition characterized by 
cutaneous neurilemmomas and central nervous system schwannomas. More recently, a third 
group of patients, with familial clear cell meningiomas, were identified to harbor germline 
mutations in SMARCE1 (Smith et al., 2013). However, a small group of familial meningioma 
patients, with intracranial multiple tumors, describe a distinct entity without association to the 
abovementioned conditions. 
In study IV, we examined a Finnish family of five siblings with meningiomas, four of whom had 
multiple tumors. To identify the genetic defect, we conducted linkage analysis and sequenced the 
germline exomes of three affected family members. After combining the two data sets, 20 protein 
code altering candidate variants remained, of which 7 were further shown to segregate in all the 5 
affected meningioma patients. The presence of these seven variants was further examined in the 
healthy family members and in additional population-based controls. Two of the variants were 
excluded from further consideration, because they were present in unaffected siblings and three 
were excluded because they were present in the population-based controls, leaving two possible 
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candidate variants, namely the c.367C>T (p.Arg123Cys) in SUFU and the c.1990A>G 
(p.Ser664Pro) in AASS. From these the c.367C>T (p.Arg123Cys) in SUFU was in silico 
predicted damaging, while the c.1990A>G (p.Ser664Pro) in AASS was predicted benign. Also, no 
LOH was observed at the site of the AASS variant, whereas at the site of SUFU variant LOH was 
observed in each of the studied tumors, strongly indicating a presence of a tumor suppressor gene.   
Suppressor of Fused Homolog (Drosophila) (SUFU) is located at 10q24.32, and it encodes a key 
negative regulator of the Hedgehog signaling (Hh) pathway. The pathway is essential for correct 
embryonic development and it is present in all bilateral animals (Ingham et al., 2011; Varjosalo 
and Taipale, 2008). Hh cascade is triggered by binding of the ligand to the receptor (PTCH1 or 
PTCH2). This interaction leads to a release of SMO and activation of GLI family of transcription 
factors. The activated GLIs moves to the nucleus to regulate expression of the Hh pathway target 
genes (Varjosalo and Taipale, 2008; Ingham et al., 2011). Hh pathway is controlled by many 
molecules, but in humans SUFU is the main negative regulator (Svard et al., 2006; Varjosalo et 
al., 2006; Ruel and Therond, 2009). In addition to the central role of Hh pathway in 
embryogenesis, it is also important in the adult tissues, where it regulates the proliferation of 
various stem and progenitor cells, including neural progenitor cells (Lai et al., 2003; Varjosalo 
and Taipale, 2008). 
SUFU germline mutations predispose to medulloblastomas, which are aggressive brain tumors 
affecting generally young children (Taylor et al., 2002; Cheng and Yue, 2008). Most of the 
medulloblastoma predisposing SUFU mutations are truncating, and the tumors commonly also 
display a ‘second hit’. Somatic inactivating SUFU mutations are also often observed in 
medulloblastomas and basal cell carcinomas of the skin (Taylor et al., 2002). The SUFU 
mutation that we identified was a missense change, and thus the effect of the mutation in 
principle could be SUFU activating. However, the presenece of LOH at the site of the SUFU 
mutation in the studied meningioma tumors strongly implies that also in the case of meningiomas 
SUFU acts like a tumor suppressor gene. This was further confirmed by our in vitro experiments 
that demonstrated that the p.Arg123Cys mutation impairs the binding of SUFU with GLI1, 
disturbs the SUFU mediated nuclear-cytoplasmic shuttling of GLI1 (Kogerman et al., 1999; Shi 
et al., 2014), and significantly reduces its ability to suppress Hh pathway. Although the 
p.Arg123Cys mutation is clearly damaging for the correct functioning of SUFU, it does not 
totally abolish its function, and it is interesting to speculate that the remaining activity may 
explain the phenotypic difference between meningiomas and medulloblastomas.  
A large chromosomal deletion encompassing the long arm of chromosome 10 is also frequently 
seen in sporadic meningiomas (Louis et al., 2007). The 10q deletion has been reported to affect 
especially anaplastic, atypical and malignant meningiomas (Louis et al., 2007). The deleted 
region is usually large and involves multiple potential tumor suppressor genes. Although PTEN is 
often considered to be the main tumor suppressor gene at this region, a study comparing the 10q 
deletions in glioblastomas and meningiomas reported biallelic PTEN mutations in a subset of 
gliomas but not in meningiomas (Bostrom et al., 1998). 
In addition to medulloblastoma predisposing germline SUFU mutations, germline mutations in 
SUFU have been identified from a family and an isolated case with basal cell nevus syndrome 
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(MIM #109400) (Pastorino et al., 2009; Kijima et al., 2012). Basal cell nevus syndrome, also 
known as Gorlin syndrome, is an autosomal dominant disorder characterized by multiple basal 
cell carcinomas, odontogenic keratocysts of the jaws, and skeletal abnormalities (Lo Muzio, 
2008). Basal cell nevus syndrome is usually caused by inherited mutations in the Hh pathway 
receptor PTCH1 (Lo Muzio, 2008). In addition to basal cell carcinomas, the basal cell nevus 
syndrome patients have increased risk of medulloblastoma (Lo Muzio, 2008). Although 
meningiomas are not generally considered to belong to the tumor spectrum, some reports show 
meningiomas in patients with basal cell nevus syndrome (Tate et al., 2003; Sobota et al., 2007; 
Pribila et al., 2008; Kijima et al., 2012). Intriguingly, the isolated basal cell carcinoma patient 
with germline SUFU mutation, described by Kijima et al. had developed a meningioma (Kijima 
et al., 2012). 
Recent high-throughput sequencing studies on meningiomas have identified SMO mutations in 
about 5% of sporadic menigiomas (Brastianos et al., 2013; Clark et al., 2013). These tumors 
display a distinct meningioma entity, characterized by activated Hh pathway (Brastianos et al., 
2013; Clark et al., 2013). The SMO mutations identified in meningiomas thus far hit the same 
mutational hotspot often mutated in basal cell carcinomas and medulloblastomas (Reifenberger et 
al., 1998; Jones et al., 2012). Multiple SMO inhibitors are currently in clinical development and 
Vismodegib (GDC0449, Curis/Roche) has recently been approved by the US Food and Drug 
Administration, for the treatment of basal cell carcinomas (Rudin, 2012; Amakye et al., 2013). 
Although majority of meningiomas are treated surgically, some are inoperable and many recur 
after successful operation. Thus it would be important to study if a fraction of meningioma 
patients would benefit from treatment with SMO inhibitors. 
We identified a germline mutation in SUFU that segregates with the meningiomas in a family of 
five affected siblings. The mutation was not found from the population based healthy controls, 
and all the studied tumors displayed LOH at the site of the mutation. We also showed that the 
SUFU mutation impaired the interaction with GLI1 and led to dysregulated Hh pathway. This 
data, together with the recent discovery of SMO mutations in sporadic meningiomas, indicate that 
SUFU is a meningioma predisposition gene, and that dysregulated Hh pathway underlie the 
development of a small but significant subset of meningiomas. 
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
Cancer is one of the leading causes of disease and death world-wide, with an estimated number of 
14.1 million new cancer cases and 8 million cancer related deaths world-wide during 2012 
(Ferlay et al., 2013). Solely in Finland, 30 314 new cancers and 11 860 cancer related deaths 
were registered in 2012 (http://www.cancer.fi/syoparekisteri/en/statistics/).  
Majority of tumors occur due to environmental causes, and only a small portion occurs due to 
inherited defective cancer susceptibility genes. Many cancers also display familial aggregation 
without clear Mendelian inheritance. Various excellent molecular genetic techniques have been 
developed and widely employed during the past few decades to understand the genetic 
susceptibility to cancer, and a number of great discoveries have been made, especially in the field 
of hereditary cancer syndromes and Mendelian tumor susceptibility genes. It is sometimes 
claimed that most of the genes underlying hereditary cancer syndromes have already been 
identified. However, during the last five years, multiple novel high penetrance cancer 
susceptibility genes have been identified with the help of high-throughput sequencing methods 
(Rahman, 2014).  
This study was conducted to assess the familial aggregation of tumors in Finland, to identify 
novel tumor susceptibility families and to elucidate the genetic predisposition of familial NLPHL, 
meningioma, and KS. The conclusions are as follows: 
I) By using family name at birth and municipality at birth as identifiers for familiality, we 
performed a nation-wide assessment of familial aggregation of 183 tumor types in Finland. As a 
result we identified 25 910 birth name-municipality and tumor type based clusters and 12 695 
birth name-tumor type based clusters. We evaluated the familial occurrence of the tumor types 
and identified frequent familial clustering of KS in Finland. Furthermore, the clustered as well as 
the sporadic KS cases were shown to accumulate to the western parts of Finland, suggesting 
shared genetic or environmental factors underlying KS. We also identified a family with five 
affected individuals in two generations and several smaller families with two first degree relatives 
with KS. This work showed that the birth municipality- and birth name- based clustering is a 
powerful method to identify familial cancer cases, and future studies will hopefully elucidate the 
genetic basis of other potential predisposition conditions found in this study.  
II) To elucidate the underlying genetic factors behind classical KS, we mapped the shared 
chromosomal regions and sequenced two genomes and an exome from three affected individuals 
belonging to the Finnish family of five affected individuals. We identified 14 potential KS 
predisposing candidate variants, among them a rare missense variant c.1337C>T (p.Thr446Ile) in 
the DNA binding domain of STAT4. We showed that the healthy mutant carriers had decreased 
IFN-γ production compared to the matched wild-type controls. We conducted a search for 
additional STAT4 mutations in a large set of KS cases, but found no pathogenic changes. We also 
studied the STAT4 related genes in a set of seven familial KS cases and identified a putatively 
harmful missense change in CCR5 that was absent in the studied controls. However, further 
genetic and functional studies are needed to draw conclusions of the importance of the STAT4 
and the related genes in KS predisposition.  
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III) To study the genetic predisposition in a rare HL subtype, NLPHL, we combined genome-
wide linkage analysis and exome sequencing. A frameshift mutation in NPAT was described and 
found to segregate with NLPHL in a Finnish family with four affected cousins. Additionally, an 
in-frame deletion of serine 725 of the NPAT was detected, and it was shown to be more prevalent 
in the HL cases than in the healthy controls supporting a role of NPAT in the HL predisposition. 
However, further genetic and functional studies confirming the relevance of NPAT in the genesis 
of HL should be performed. 
IV) Linkage analysis and exome sequencing was utilized to identify a c.367C>T (p.Arg123Cys) 
mutation in SUFU underlying the intracranial meningiomas in a Finnish family of five affected 
siblings. Loss-of-heterozygosity of SUFU was observed in all the studied tumors, indicating a 
classic tumor suppressor gene function for SUFU. In vitro and in silico experiments were 
conducted, and the SUFU mutation was shown to affect its function and lead to constitutively 
activated Hh pathway. We studied a large number of meningioma cases to identify additional 
SUFU mutations, but were unable to detect any mutations that would have been pathogenic. 
Recent studies in sporadic meningioma have revealed Hh pathway dysfunction in approximately 
5% of meningiomas (Brastianos et al., 2013; Clark et al., 2013). Larger studies revealing the 
extent of Hh pathway dysregulation in menigiomas are needed.  
The few past few years have witnessed a revolution in the field of human genetics. The 
sequencing of the first haploid human genome took over ten years and an incredible amount of 
work and effort from hundreds of scientists. Today it is feasible to sequence a genome of an 
individual within one working day. The development of novel sequencing methods has not 
ceased, and new techniques are constantly developed. Little by little, as their use has become 
more routine, high-throughput sequencing based methods are entering clinical use, and hopefully 
in the near future the era of actual personalized medicine will become reality.  
As any new technology, the high-throughput sequencing methods also provide many new 
challenges. Increasing amount of rare variants, both in patients and the general population are 
detected. Determining the true disease related variants from individual rare variation is not trivial, 
especially in the cases of very rare conditions, where it is difficult to find supportive genetic 
evidence. A rigorous validation, both functional and genetic, will be needed, and causative 
variants are to be “handled with care”, that is, to be claimed causative only with solid evidence. 
Most likely international collaboration and meta-analytical approaches will help in this.  
Although the new techniques have opened up possibilities to almost any scientist to zoom in to 
the base-pair level of individual genomes, a utopist dream that a geneticist might have had a few 
decades ago, we still have only a vague understanding of the causes of familial clustering of 
cancers outside the framework of monogenic inheritance. To be able to tackle the etiology of 
familial aggregation outside monogenic inheritance, increased understanding of the regulatory 
genome and gene-environment interplay will be needed. 
Finland has long traditions in successful genetic research. Many factors have contributed to this, 
including comprehensive public health care system, high quality nation-wide registry 
infrastructure, as well as the genetic background of the Finnish population. Important aspects 
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include also the willingness of the Finns to participate in genetic studies and the Finnish 
legislation, which generally supports registry-based studies. This thesis work utilized the 
possibility to conduct a registry-based population-level study on familial aggregation of tumors 
and focused on the identification of novel high and moderate risk genetic alterations from Finnish 
families with rare and common tumor types. The work would not have been possible without the 
willingness of the families to participate in the study, or without the excellent data at the FCR, 
not forgetting the Finnish legislation supporting the conduction of these kinds of studies, and it is 
certainly crucial that the situation remains the same in the future.   
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